Plug Power prodává projekt v Grahamu v Texasu a upravil dohodu o Gateway v New Yorku se Stream Data Centers. Očekává z toho až přibližně 90,5 milionu USD krátkodobé likvidity.
SLINGERLANDS, N.Y., July 13, 2026 (GLOBE NEWSWIRE) -- Plug Power Inc. (NASDAQ: PLUG) today announced two transactions with Stream US Data Centers, LLC ("Stream"), advancing the Company’s previously announced strategic infrastructure optimization initiatives, which collectively target more than $275 million in liquidity improvement through a combination of asset monetization, release of restricted cash, and reduced maintenance expenses. In addition, Stream and Plug Power are now also actively exploring other opportunities for Plug to deploy its products into the data center industry. Plug previously announced in February 2026 that it had entered into a definitive agreement to sell its interest in the New York Gateway Project to Stream. As the parties continued to work toward satisfaction of the transaction's closing conditions, including applicable regulatory and project-related approvals, the parties agreed to restructure the transaction into a staged closing and to enter into a definitive agreement for the sale of Plug’s Graham, Texas Project.
Texas
Plug has signed a definitive agreement to sell its Graham, Texas Project, comprised of land and associated 164 MW of grid interconnection assets, to Stream for up to $76.5 million, with $50 million to be paid at closing and up to $26.5 million based on the load capacity that will be confirmed in the final interconnection agreement with the Texas utility. The closing is expected on or about July 31, 2026, subject to the satisfaction of closing conditions. The sale is also expected to enable the release of approximately $14 million of cash collateral currently supporting letters of credit/security payments, following the transfer of the applicable interconnection-related obligations and security arrangements to Stream. In total, this transaction is expected to provide up to approximately $90.5 million of total liquidity.
New York
Plug and Stream have amended the purchase and sale agreement for the Gateway Project as follows: (i) Stream's prior $6.5 million escrow deposit will be promptly released to Plug; (ii) Stream will make a new $10 million escrow deposit toward its purchase of land at the Gateway site; (iii) the closing provisions have been amended to enable the near-term sale of the land; and (iv) the long-stop closing date for the sale of non-land assets has been extended to March 31, 2027 to afford additional time for completion of the applicable New York State environmental and regulatory review processes and satisfaction of the remaining closing conditions. As amended, the purchase price is fixed at $142 million. Combined with a $5 million advance received earlier this year, Stream will have paid $21.5 million to Plug against the purchase price upon release of the escrow deposits described above. Plug will retain ownership of the substation and interconnection assets, along with a repurchase right over the land, until the second closing.
Liquidity
As of June 30, 2026, Plug held approximately $162 million of unrestricted cash and cash equivalents, before giving effect to any proceeds from the transactions announced today. Together, the initial New York closing and the Texas transaction represent additional progress under Plug’s previously announced strategic infrastructure optimization initiative and are expected to deliver more than $80 million of near-term incremental liquidity. Additional initiatives under Plug’s previously announced strategic infrastructure optimization initiative, including further anticipated releases of restricted cash, are advancing and are expected to bring aggregate liquidity improvement of more than $275 million.
"Plug is appreciative of the continued collaboration and partnership with Stream Data Centers and is excited to position for closing in the near term. Monetizing these assets was a key part of our strategy this year, coupled with the continued improvements in margin and cash flows to fund the business. We look forward to sharing our results for the second quarter shortly and believe that we are on track with our financial goals for 2026. The improvement in margins, effective management of our liquidity, and the growth of our sales pipeline remain our critical focus." said Jose Luis Crespo, Chief Executive Officer and President of Plug Power.
About Plug Power
Plug is building the global hydrogen economy with a fully integrated ecosystem spanning production, storage, delivery, and power generation. A first mover in the industry, Plug provides electrolyzers, liquid hydrogen, fuel cell systems, storage tanks, and fueling infrastructure to industries such as material handling, industrial applications, and energy producers, advancing energy independence and decarbonization at scale.
With electrolyzers deployed across six continents, Plug leads in hydrogen production, delivering large-scale projects that redefine industrial power. The company has deployed more than 74,000 fuel cell systems and over 280 fueling stations and is the largest user of liquid hydrogen. Plug is rapidly expanding its generation network to ensure reliable, domestically produced supply, with hydrogen plants currently operational in Georgia, Tennessee, and Louisiana, capable of producing up to 40 tons per day.
Headquartered in Slingerlands, New York, Plug is driving innovation, strengthening American manufacturing, and creating high-quality jobs across the country. The company employs more than 730 people in New York, supporting approximately $69 million in annual payroll, and nearly 200 employees in Texas, representing more than $18 million in annual payroll. Across New York and Texas, Plug has deployed more than 6,200 GenDrive fuel cell-powered forklifts at 31 customer facilities, helping customers reduce electricity demand, avoid nearly 95,000 MWh of annual electricity consumption, prevent more than 33,000 metric tons of CO2 emissions each year, and eliminate approximately $164 million in electric infrastructure investments that would otherwise have been borne by utility customers and ratepayers. With employees and state-of-the-art manufacturing facilities across the globe, Plug powers industry leaders including Walmart, Amazon, Home Depot, BMW, and BP.
FORWARD-LOOKING STATEMENTS
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical facts, including, without limitation, statements regarding the Company's expectations, goals, plans, outlook or prospects, including expected gross proceeds and total proceeds from the transactions, the timing and likelihood of each closing, the anticipated receipt and amount of contingent consideration, the anticipated release of cash collateral, the anticipated aggregate liquidity improvement under the Company's strategic infrastructure optimization initiative, the Company's ability to execute its business strategy and achieve its financial goals for 2026, the Company's ability to pursue additional opportunities with Stream in the data center industry, the timing and outcome of New York State's environmental and regulatory review processes, the Company's preliminary and unaudited cash position as of second quarter of 2026, and other statements regarding future operating results, financial condition, performance, prospects, and opportunities, are forward-looking statements. These forward-looking statements are based on current expectations, estimates, forecasts, and projections and the beliefs and assumptions of management and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. These risks and uncertainties include, among other things: the Company's ability to satisfy closing conditions and complete each transaction on the anticipated terms or at all; the risk that the New York State environmental and regulatory review process applicable to the Gateway Project site is delayed or does not result in the determinations necessary to permit the second closing; the risk that the final interconnection agreement with the Texas utility is not executed or does not confirm the anticipated load capacity, which could reduce or eliminate the contingent consideration payable under the Graham, Texas Project transaction; the risk that escrow deposits are not released on the anticipated timeline or at all; general market, economic, competitive, and regulatory conditions; the effectiveness of the Company's strategic initiatives, including the infrastructure optimization initiative; risks associated with the data center market and demand for power solutions; the Company's ability to manage costs and liquidity; risks related to the Company's future capital requirements and liquidity needs; and other factors detailed from time to time in the Company's filings with the Securities and Exchange Commission (the 'SEC'), including the Company's Annual Report on Form 10-K for the year ended December 31, 2025, subsequent Quarterly Reports on Form 10-Q, and other reports filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
The GEO Group uzavřela pětiletou smlouvu s ICE na spuštění federálního imigračního centra v zařízení Big Horn Facility v Hudsonu v Coloradu s kapacitou 1 188 lůžek. V prvním plném roce má přinést asi 85 milionů USD ročních tržeb bez dopravy.
BOCA RATON, Fla.--(BUSINESS WIRE)--The GEO Group, Inc. (NYSE: GEO) (“GEO” or the “Company”) announced today that the Company has entered into a five-year support services contract with U.S. Immigration and Customs Enforcement (“ICE”) for the activation of a federal immigration processing center at the 1,188-bed Big Horn Facility (the “Facility”) in Hudson, Colorado. GEO has entered into a lease agreement with the Facility owner.
The support services contract is expected to generate approximately $85 million in annual revenues in the first full year of operations, excluding transportation revenue. GEO’s support services are expected to include the exclusive use of the Facility by ICE, along with security, maintenance, and food services, as well as access to recreational amenities, medical care, and legal counsel.
George C. Zoley, GEO's Chairman, Chief Executive Officer and Founder, said, “We expect that our company-leased Big Horn Facility in Colorado will play an important role in helping meet the need for increased federal immigration processing center bedspace. We are proud of our 40-year public-private partnership with ICE, and we stand ready to continue to assist the federal government in meeting its immigration enforcement priorities.”
About The GEO Group
The GEO Group, Inc. (NYSE: GEO) is a leading diversified government service provider, specializing in design, financing, development, and support services for secure facilities, processing centers, and community reentry centers in the United States, Australia, South Africa, and the United Kingdom. GEO’s diversified services include enhanced in-custody rehabilitation and post-release support through the award-winning GEO Continuum of Care®, secure transportation, electronic monitoring, community-based programs, and correctional health and mental health care. GEO’s worldwide operations include the ownership and/or delivery of support services for 97 facilities totaling approximately 76,000 beds, including idle facilities and projects under development, with a workforce of up to approximately 20,000 employees.
Use of forward-looking statements
This news release may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements and any such forward-looking statements are qualified in their entirety by reference to the cautionary statements and risk factors contained in GEO's filings with the U.S. Securities and Exchange Commission including its Form 10-K, 10-Q and 8-K reports. All forward-looking statements speak only as of the date of this news release and are based on current expectations and involve a number of assumptions, risks and uncertainties that could cause the actual results to differ materially from such forward-looking statements. Readers are strongly encouraged to read the full cautionary statements and risk factors contained in GEO’s filings with the U.S. Securities and Exchange Commission, including those referenced above. GEO disclaims any obligation to update or revise any forward-looking statements, except as required by law.
Ocugen podepsal závazný term sheet s Roots Pharmaceutical pro exkluzivní licenci na OCU400 v regionu MENA. Firma může získat až 4 miliony USD předem a krátkodobě, plus až 255 milionů USD na milnících a 22% royalty z čistých tržeb.
Cumulative sales milestones up to $255 million and modest upfront/near-term development milestonesRoyalties equaling 22% of net salesOcugen to manufacture and supply OCU400 MALVERN, Pa., July 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the signing of a binding term sheet to negotiate and enter into a license agreement with Roots Pharmaceutical, and its strategic partner Al-Dhow International Holding, for the exclusive rights to OCU400, Ocugen's novel modifier gene therapy for Retinitis Pigmentosa (RP), in the Middle East and North Africa (MENA) region.
Pursuant to the term sheet, under the license agreement, Ocugen is expected to receive upfront license fees and near-term development milestone payments totaling up to $4 million. The Company would be entitled to sales milestone payments up to $255 million, in addition to a 22% royalty on net sales of OCU400 generated by Ocugen's partner. Additionally, Ocugen would manufacture commercial supply of OCU400 under the terms of a related supply agreement.
RP is a leading cause of inherited vision loss globally, with notable prevalence across the MENA region, underscoring the significant unmet need OCU400 is positioned to address through this partnership.
"This step forward represents an important milestone in our effort to advance OCU400 regional partnership strategy," said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. "By partnering with an established leader with strong reach across the Middle East and North Africa, we are expanding our ability to bring this one-time potential treatment for life to a region where RP is highly prevalent with a significant unmet medical need where patients are desperately looking for rescue from blindness. This agreement underscores the momentum behind OCU400 and our continued commitment to patients."
“Bringing innovative gene therapies to patients across the MENA region is a strategic imperative for Roots Pharmaceutical and its strategic partner Al-Dhow International Holding,” said Dr. Islam Zayed, CEO & Co founder of Roots Pharmaceutical. Dr.Zayed emphasized that “ OCU400 built on our legacy of bringing Rare Disease therapies to patients in MENA and enables our combined teams to decrease disease burden in the region. Importantly, Roots is dedicated to bringing OCU400 to patients with Retinitis Pigmentosa and creating a new treatment paradigm. We are excited to partner with the Ocugen team.”
Additional details will be available once the definitive agreement between the parties is executed, which is expected to occur within the next 90 days.
Ocugen continues to advance OCU400 through its Phase 3 liMeliGhT clinical development with a topline readout expected in 1Q 2027 and BLA submission to follow.
About Ocugen, Inc.
Ocugen, Inc. is a pioneering biotechnology leader in gene therapies for blindness diseases. Our breakthrough modifier gene therapy platform has the potential to address significant unmet medical need for large patient populations through our gene-agnostic approach. Unlike traditional gene therapies and gene editing, Ocugen’s modifier gene therapies address the entire disease—complex diseases that are potentially caused by imbalances in multiple gene networks. Currently we have programs in development for inherited retinal diseases and blindness diseases affecting millions across the globe, including retinitis pigmentosa, Stargardt disease, and geographic atrophy—late-stage dry age-related macular degeneration. Discover more at www.ocugen.com and follow us on X and LinkedIn.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the terms of the definitive license and supply agreement with Roots Pharmaceutical, the timing of entering into such definitive agreement or whether such definitive agreement will be executed at all, the anticipated benefits to Ocugen of such definitive agreement, qualitative assessments of available data, potential benefits, expectations for ongoing clinical trials, anticipated regulatory filings and anticipated development timelines, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations, including, but not limited to, the risks that the definitive license and supply agreement with Roots Pharmaceutical will be delayed or not executed at all, or that, if executed, it will not be on terms described above, the risk that such definitive agreement, if executed, will not lead to the currently anticipated benefits to Ocugen, the risks that preliminary, interim and top-line clinical trial results may not be indicative of, and may differ from, final clinical data; that unfavorable new clinical trial data may emerge in ongoing clinical trials or through further analyses of existing clinical trial data; that earlier non-clinical and clinical data and testing may not be predictive of the results or success of later clinical trials; and that that clinical trial data are subject to differing interpretations and assessments, including by regulatory authorities. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.
Elevance Health a UnitedHealth tento týden zveřejní výsledky, které ukážou, zda se po období vyšších nákladů na zdravotní péči daří pojišťovnám držet náklady na uzdě. Sledují se hlavně plány Medicare Advantage.
This week’s Elevance Health and UnitedHealth Group quarterly earnings are much anticipated for signs these companies’ health insurance businesses and their rivals are keeping a handle on rising costs. In this photo, UnitedHealthcare health insurance company signage is displayed on an office building in Phoenix, Arizona on July 19, 2023. (Photo by Patrick T. Fallon / AFP) (Photo by PATRICK T. FALLON/AFP via Getty Images)
AFP via Getty Images
This week’s Elevance Health and UnitedHealth Group quarterly earnings are much anticipated for signs these companies’ health insurance businesses and that of their rivals are keeping a handle on rising costs.
Elevance, which owns Blue Cross and Blue Shield plans in 14 states, and UnitedHealth, which owns the nation’s largest health insurer in UnitedHealthcare, will be the first health insurers to report second quarter earnings as the industry works to exit a period of higher-than-expected medical costs.
These insurers’ earnings reports report will offer clues as to whether the sector may finally be turning the corner after most health plans reported medical loss ratios north of 90% until the trend was interrupted with lower costs in the first quarter of this year. Such a ratio, which is the percentage of premium revenue that goes toward medical costs, was above 90% for much of 2025 for many insurers.
In the first quarter of this year, however, Elevance, which is the nation’s second-largest health insurer behind UnitedHealthcare, reported a benefit expense ratio eclipsing 86%. Elevance manages Medicaid coverage for poor Americans via contracts with multiple states, sells Medicare Advantage for older adults and markets commercial health insurance including individual coverage under the Affordable Care Act, also known as Obamacare. The company also has a growing Carelon healthcare services business.
“The benefit expense ratio was 86.8 percent, an increase of 40 basis points, reflecting expected elevated medical cost trend in our Medicaid business, partially offset by improved performance in Medicare,” Elevance Health said in its first quarter earnings statement.
MORE FOR YOU
Analysts who follow the industry say they expect second quarter earnings reports to show that companies have maintained their handle on medical cost trends, particularly in their Medicare Advantage plans. Medicare Advantage plans contract with the federal government to provide coverage available in traditional Medicare plus extra benefits and services to seniors, such as disease management and nurse help hotlines with some also offering vision, dental care and wellness programs.
UnitedHealth said in its first quarter report that its “medical cost ratio was 83.9% for the first quarter 2026, down 90 basis points from the first quarter 2025.”
Elevance reports Wednesday, July 15 and UnitedHealth reports Thursday, July 16.
Zlato po pondělním gapu dolů o 20 USD zůstává pod tlakem a trh sleduje klíčovou podporu 4 000 USD. Její proražení by potvrdilo pokračování medvědího trendu.
Gold edged lower after opening with $20 gap lower on Monday, following the latest escalation in the Middle East that fueled inflationary risk and added to expectations that the Fed will keep higher interest rates or possibly opt for rate hikes, providing support to US dollar.
Markets also focus on this week’s key economic data – release of US June inflation report and Fed Chair Warsh’s semiannual testimony on economy, inflation and monetary policy that will add fresh details on overall outlook.
Technical studies on daily chart remain in mainly bearish configuration, following several death-crosses formed during June (20; 30; 55 / 200DMAs), 14-d momentum holding in negative zone and RSI below 50).
Fresh weakness after recent recovery stall, shifts near-term focus to the downside, with initial requirement on weekly close below Fibo support at $4076 (where bears were rejected four times) guarding key supports at $4000/$3950 (psychological / recent spikes below $4K), with firm break here (after a multiple failure) to generate bearish continuation signal of larger downtrend from new historical high.
At the upside, falling 20DMA marks first significant resistance ($4118), ahead of pivotal barrier at $4203 (July 6 recovery peak).
The information contained in this document was obtained from sources believed to be reliable, but its accuracy or completeness cannot be guaranteed. Any opinions expressed herein are in good faith, but are subject to change without notice. No liability accepted whatsoever for any direct or consequential loss arising from the use of this document.
Bloom Energy rozšířila s Brookfield Asset Management financování na nasazení palivových článků z 5 miliard USD na 25 miliard USD. Jde o rámec financování pro AI datová centra, ne o okamžité tržby.
Take a second and imagine the nearly 3,000 data centers currently under construction or planned in the U.S. all being finished at about, or nearly about, the same time. What a great day for artificial intelligence (AI) companies that will be, right? Yes, but only if they can solve a pesky bottleneck that threatens to derail their plans: power supply.
Let me rephrase the problem like this (and then we'll get to the stock under consideration): A hyperscale data center can take about two to three years to finish, yet it can take anywhere from four to five years or more to connect that center to the electric grid.
Those aren't numbers I pulled out of my head. They come from a recent article published in Energy Reports, which also adds this as a solution: "To address this challenge, scalable transmission switchyards and on-site power generation solutions are critical."
I don't write much about "scalable transmission switchyards" (yet), but one company I cover has been supplying "on-site power generation" to customers for years. That stock is Bloom Energy (BE 4.74%), and the rampant data center build-out mentioned above has just helped them expand a multibillion-dollar agreement fivefold.
Image source: Bloom Energy.
A financing framework that removes a major hurdle Bloom Energy sells solid oxide fuel-cell systems -- essentially modular boxes that produce on-site power. These boxes, or servers, essentially convert fuel such as natural gas into electricity without combustion. The company has already deployed servers at over a thousand sites in nine countries, and, as its recent deals suggest, deployments could accelerate considerably.
Last October, Bloom announced a partnership with Brookfield Asset Management (BAM +1.19%). Under the terms of this agreement, Brookfield committed up to $5 billion to finance deployments of Bloom's fuel cell technology and named Bloom its preferred provider of on-site power for AI infrastructure.
Recently, at the end of June, Brookfield decided that demand for data centers wasn't weakening and expanded the original financing deal to $25 billion.
Obviously, $25 billion sounds like a lot. But don't overlook that important qualifier. This deal is a financing framework, not a commitment to revenue. Bloom isn't getting $25 billion upfront from Brookfield. Instead, it's getting a promise that Brookfield will help potential customers of Bloom finance the fuel cell maker's servers, which aren't cheap.
That financing can turn into revenue over time, but it's important that investors don't mistake it for sales yet.
Today's Change
(
-4.74
%) $
-12.17
Current Price
$
244.85
Bloom stock has fallen about 29% since the news broke, mainly due to general market volatility and a recent short-seller report. As such, Bloom currently trades around its level at the beginning of June, just before it climbed 40%.
For long-term investors, now might be a good time to buy Bloom. The demand for on-site power generation isn't going away anytime soon, and the Brookfield financing is making it easier for potential customers to adopt Bloom's technology. Expect short-term volatility, but over the long run, this energy stock is poised for growth.
Binance pozastaví vklady a výběry na síti Moonbeam (GLMR) kvůli upgradu sítě, obchodování zůstane beze změny. Po stabilizaci sítě budou vklady a výběry obnoveny.
This is a general announcement. Products and services referred to here may not be available in your region. Fellow Binancians, Starting at approximately 2026-07-13 12:00 (UTC), Binance will suspend the deposits and withdrawals of token(s) on the Moonbeam (GLMR) network to support its network upgrade to ensure the best user experience. The network upgrade will take place at the block height of 16,427,124, or approximately at 2026-07-13 13:00 (UTC). Please note: The trading of token(s) on the aforementioned network will not be impacted.Binance will handle all technical requirements involved for all users.Deposits and withdrawals for token(s) on the aforementioned network will be reopened once the upgraded network is deemed to be stable. No further announcement will be posted.There may be discrepancies between this original content in English and any translated versions. Please refer to the original English version for the most accurate information, in case any discrepancies arise. For more information, please refer to the announcement from the project team. Thank you for your support! Binance Team 2026-07-13
Elevion Group podepsal kupní smlouvu na akvizici 100% podílu v italské společnosti BTS Biogas. Posílí tak v sektoru bioplynových a biometanových stanic.
Společnost ČEZ, a.s. zveřejňuje vnitřní informaci Elevion Group podepsal kupní smlouvu na akvizici 100% podílu v italské společnosti BTS Biogas, posílí tak v sektoru bioplynových a biometanových stanic. Více informací zde.
(komerční sdělení)
Tagy: Povinně uveřejňované informace
Reklama
Na tomto místě můžete zahájit diskusi. Zatím nebyl zadán žádný názor. Do diskuse mohou přispívat pouze přihlášení uživatelé (Přihlásit). Pokud nemáte účet, na který byste se mohli přihlásit, registrujte se zde.
Aktuální komentáře
13.07.2026 11:41ČEZ, a.s.: Vnitřní informace - Elevion Group podepsal kupní smlouvu na akvizici 100% podílu v italské společnosti BTS Biogas 10:58TSMC má za druhé čtvrtletí rekordní tržby 10:07Nejhorší den na burze. Akcie SK Hynix potkal více než 15procentní výplach 8:52Eskalace konfliktu s Íránem zhoršuje náladu na trzích. SK Hynix po americkém debutu propadl 8:47Rozbřesk: Hormuz znovu straší trhy. Česká ekonomika však drží kurz 6:03Wood: Úvahy o konci americké výjimečnosti jsou notně přehnané 12.07.2026 9:22Víkendář: Greenspan předpovídal inflaci 4,5 % a 8% výnosy z desetiletých amerických státních dluhopisů 11.07.2026 9:21Víkendář: Greenspan se evidentně mýlil, akcie nebyly v roce 1996 nijak nadhodnocené 10.07.2026 17:39Nemělo by se nyní více mluvit o nesprávném monetárním kurzu? 16:08Bylo by nebezpečné vědět, proč centrální banky jednají tak, jak jednají? 14:10Analytici otáčejí. Očekávání zisků evropských firem rostou nejrychleji za dva roky 12:22Perly týdne: Červená karta pro Američany a klesající dynamika akcií malých firem 11:02Volkswagen spouští jednu z největších proměn ve své historii. Omezí výrobu i nabídku modelů 10:51Techy korigují včerejšek, ale trhy mezitím podporuje obnovení jednání s Íránem 10:41ExxonMobil může těžit z návratu geopolitických rizik. Má prostor pro růst akcií 9:24O easyJet se rozhořel boj. Apollo nabídlo víc než konkurence a získalo podporu vedení 9:01Rozbřesk: Polská centrální banka drží sazby, Glapiński se nebrání podzimnímu snížení 8:54Babiš otevřel debatu o IPO Letiště Praha, ČNB varuje před návratem inflace a optimismus kolem AI se vrací 6:04Nejvýnosnější akciový trh roku? Jižní Koreu sesadila Nigérie 09.07.2026 17:25Pracují nyní trhy pro Fed nebo proti němu? A jak dopadnou testy nových monetární myšlenek?
Reklama
Cathie Wood přes Ark Invest dál nakupuje CoreWeave, i když akcie od 18. června klesly o 23 %. ARKK už drží 1,6 milionu akcií za zhruba 146 milionů USD.
Cathie Wood, founder and CEO of Ark Invest, is loading up on an AI stock that the market has been dumping in recent weeks, CoreWeave (CRWV 0.87%).
Ark's largest exchange-traded fund (ETF), the ARK Innovation ETF (ARKK 1.58%), has added more than 100,000 shares of CoreWeave in recent weeks. On July 8, Wood bought $811,600 worth of shares. That followed a $2 million purchase on July 7. Wood also purchased $6.5 million worth of shares on June 29, according to Cathie's Ark.
Today's Change
(
-0.87
%) $
-0.78
Current Price
$
88.92
ARKK now owns 1.6 million shares of CoreWeave, a roughly $146 million stake. It is the ETF's 17th-largest holding, making up 2.2% of the $6.5 billion portfolio.
Wood is going against the tide, as CoreWeave stock had been in a freefall. Since June 18, when CoreWeave was trading at $118 per share, the stock has plummeted 23% to around $90 per share. There are several reasons why the stock has dropped so sharply.
Image source: Getty Images.
Explosive growth CoreWeave is a cloud computing specialist that builds AI data centers. It rents out computing power to other companies to use to handle their cloud computing needs.
CoreWeave has enjoyed explosive growth, with revenue up 114% year over year in the first quarter to $2.1 billion. Demand remains high, as CoreWeave reached nearly $100 billion in backlog in Q1.
Its outlook calls for revenue of $2.45 billion to $2.6 billion and adjusted operating income of $30 million to $90 million in the second quarter. For the full year, revenue is targeted at $12 billion to $13 billion, with adjusted operating income at $900 million to $1.1 billion.
While the growth is staggering, the concern is high expenses and debt. This is an asset-heavy business that requires massive infrastructure investments. Capital expenditures (capex) were $6.8 billion in Q1, and the company guided for between $7 billion and $9 billion in the second quarter. It also raised its full-year capex forecast to $31 billion to $35 billion on higher component pricing. Previously, the guidance called for $30 billion in capex.
CEO Michael Intrator said on the fourth-quarter 2025 earnings call that it was due to "the extraordinary amount of contracted demand in front of us."
Debt and other concerns The company has accumulated a huge amount of debt -- about $35 billion, up from roughly $2 billion in 2023.
CoreWeave is also unprofitable, reporting a net loss of $740 million in the quarter, up from $315 million in Q1 2025.
Another recent concern is the news that Meta Platforms (META +5.97%), CoreWeave's largest customer, is looking to sell its excess computing power. While nothing is concrete at this point, it raises concerns that Meta's foray into cloud could essentially turn Meta into a competitor, not a partner. CoreWeave stock tanked 14% on the news.
Wood bought these CoreWeave shares after the news broke, so she's buying low and perhaps doesn't view this as a long-term threat. That gamble may work for her, but the average investor without her resources should view CoreWeave cautiously.
Nike je asi 44 % pod 52týdenním maximem a CEO Elliott Hill nakupuje akcie poblíž letošních minim. Čtvrtletní zisk ale výrazně nafoukl jednorázový refund cla.
Shares of Nike (NKE +3.72%) closed Friday at about $44, up nearly 4% and extending a rebound that began when the company reported fiscal fourth-quarter results at the end of June. Even after that bounce, the stock sits about 44% below its 52-week high of $80.17.
Adding to the intrigue is CEO Elliott Hill, who has been putting his own money into the stock near its lows. This begs the question: Is this a good time to follow the CEO into the stock?
Image source: The Motley Fool.
A profit built mostly on a refund Nike's fiscal fourth quarter of 2026 (the period ended May 31, 2026) looked, at a glance, like a breakout. Revenue came in at $11.0 billion, and net income jumped 407% year over year to $1.1 billion. Diluted earnings per share reached $0.72.
But most of that bottom-line surge traces to a single item. Of the $0.72 in earnings per share, $0.52 came from an expected recovery of import duties Nike had paid under the International Emergency Economic Powers Act (IEEPA) -- a nearly $1 billion accounting benefit booked after courts struck down the tariffs. Strip it out, and the company earned about $0.20 per share from running its business.
The same distortion shows up in margins. Nike's gross margin jumped about 9 percentage points, to 49.2%. But almost all of that came from the tariff recovery. Strip it out, and the underlying gross margin was roughly flat -- near 40%, about where it sat a year earlier.
Fourth-quarter revenue fell 1% year over year, and dropped 4% on a currency-neutral basis, which strips out the effect of a weaker dollar. That currency-neutral decline widened as the year went on, from about 1% in the fiscal first quarter to 4% in the fourth. For the full year, sales were essentially flat -- a stabilization after the prior year's steep drop, not yet a recovery. So the reported steadiness owed something to currency, and the profit jump owed almost everything to a one-time refund.
North America is the part that's turning Underneath the noise, though, one figure suggests the turnaround is more than a story management is telling. Revenue in North America, Nike's largest market, rose 3% year over year to $4.83 billion in the quarter, and climbed 5% for the full fiscal year. After a long slide, Nike's home market is finally growing again, led by a rebound in its wholesale channel as the company rebuilds relationships with the retail partners it had spent years walking away from.
Meanwhile, Greater China, once one of Nike's most dependable growth drivers, fell another 12% in the quarter and 11% for the full year. And Nike Direct, the company's own stores and app, kept sliding, as management deliberately routes more sales back through wholesale partners.
In other words, North America is inflecting, but it hasn't yet pulled the whole company back to growth.
Then there's the insider buying. CEO Elliott Hill has twice put about $1 million of his own money into Nike shares on the open market -- once in late December, near $61 a share, and again in April, near $42, close to the stock's low. Other insiders bought around the same time, including board member Tim Cook -- the CEO of Apple.
Of course, insider purchases guarantee nothing about the stock's prospects. Even inside executives can misjudge their own companies. But a chief executive buying more as the price falls at least signals that the people closest to the business think it's worth more than the market does. So, it's at least worth some consideration.
Today's Change
(
3.72
%) $
1.59
Current Price
$
44.37
But what about the stock's valuation?
At about $44, Nike trades at about 21 times earnings. But that multiple is inflated by the one-time tariff benefit baked into the past year's profit. Strip it out, and the price-to-earnings ratio is closer to 28 -- hardly a bargain for a business whose sales are still shrinking outside North America.
So, is the stock a buy here? I'm encouraged, but I'm not buying yet. The recovery in North America and Hill's willingness to buy near the lows are the most convincing signs of a turnaround Nike has offered investors in a while. But the headline profit leans on an accounting item that won't return, and the parts of the business that most need to inflect -- Greater China and the direct-to-consumer channel -- still haven't. At this valuation, I'd want to see companywide sales turn positive on a currency-neutral basis and China stop falling before treating the turnaround as more than early. Until then, I'm content to watch a genuinely improved story get a quarter or two closer to proving itself.
Delta potvrdila výhled EPS 6,50 až 7,50 USD a volný cash flow 3 až 4 mld. USD i přes rekordní náklady na palivo. Tržby z prémiových služeb vzrostly o 17 % a z věrnostního programu o 19 %.
Key Takeaways Delta maintained 2026 EPS of $6.50-$7.50 and free cash flow of $3-$4B despite record fuel costs.DAL's premium revenues rose 17%, loyalty 19%, cargo 39% and MRO 32% as broad demand stayed intact.Delta expects 2-3% fourth-quarter capacity growth, led by larger aircraft and international expansion. Delta Air Lines, Inc. (DAL - Free Report) used its second-quarter 2026 earnings call to deliver a clear message. Pricing discipline, diversified revenues and measured capacity are helping offset a sharp fuel headwind. Management framed the quarter less as a beat and more as proof that the model is holding up.
That mattered because Delta reaffirmed its full-year earnings and free cash flow outlook even after absorbing what executives described as the highest quarterly fuel cost in company history. The call also gave investors a firmer read on industry pricing, corporate demand and 2027 setup.
DAL Leans on Revenue DurabilityChief executive officer Ed Bastian said Delta’s diversified model is gaining strength as customers keep prioritizing travel and premium experiences. He tied that resilience to loyalty, corporate share, international exposure, cargo and maintenance revenues rather than to fare increases alone.
The company reported adjusted earnings of $1.56 per share, which surpassed the Zacks Consensus Estimate of $1.51. Revenues rose 13.9% year over year to $17.67 billion, which missed the Zacks Consensus Estimate of $17.76 billion by 0.53%.
Management emphasized that this performance came on roughly 1% capacity growth, reinforcing the idea that yield and mix, not aggressive expansion, are driving the current earnings profile.
Delta Keeps Full-Year Targets IntactThe clearest signal from the call was unchanged full-year guidance. Delta reaffirmed 2026 adjusted EPS of $6.50 to $7.50, free cash flow of $3 billion to $4 billion.
For the September quarter, management guided to mid-teens revenue growth, an operating margin of 11% to 13% and EPS of $2 to $2.50. Chief financial officer Erik Snell said that the outlook assumes an all-in fuel price of about $3.15 per gallon, including a refinery benefit of $0.05 per gallon.
Snell also said nonfuel unit cost performance should improve modestly in the third quarter and progress further in the December quarter, which he positioned as a step back toward Delta’s long-term low-single-digit CASM-ex framework.
DAL Sees Structural Change in PricingBastian was especially direct in Q&A on the industry backdrop. In response to a Deutsche Bank question, he argued that higher fuel, labor, airport and aircraft costs have forced structural changes across U.S. airlines, reducing the old low-cost carrier playbook’s ability to pressure fares.
He said Delta believes current revenue momentum can persist even if fuel moderates because fares still lag cumulative inflation since COVID, and much of the industry remains below its cost of capital. That was one of the clearest indications on the call that management sees the pricing environment as more durable than cyclical.
Joe Esposito, executive vice president and chief commercial officer, reinforced that point by saying Delta exited the quarter with a materially stronger TRASM run rate than it entered, as newer, higher-priced bookings replaced earlier sales made before the fuel recapture push took hold.
Delta Finds Strength Beyond Main CabinEsposito said broad demand strength remained intact across customer groups, with premium revenues up 17%, loyalty and related revenues up 19%, cargo up 39% and MRO revenues up 32% in the quarter. American Express remuneration rose 16% to $2.4 billion.
In prepared remarks and Q&A, management highlighted an improving balance between premium and main cabin trends. Esposito told Goldman Sachs that the main cabin unit revenues outperformed premium in the quarter as industry discount capacity came out, while premium demand still produced high-single-digit unit revenue growth.
Corporate sales also drew attention. Esposito said every sector posted double-digit growth, and he told Goldman Sachs that most of the roughly 20% increase reflected fare strength rather than a major volume rebound, leaving room for upside if volumes improve further.
DAL Uses Balance Sheet and Fleet as OffenseDelta ended the quarter with adjusted net debt of $13.6 billion and liquidity of $7.7 billion, while first-half operating cash flow reached $4.1 billion and free cash flow totaled $1.4 billion. Debt reduction remained a stated priority even as the company raised its dividend by 15%.
Management also tied future margin expansion to fleet upgauging, operational resilience and international growth. Bastian said Delta expects to return to a more normal 2% to 3% capacity growth rate in the fourth quarter, with growth centered on larger-gauge aircraft and selective international opportunities.
On execution, chief operating officer Dan Janki pointed to better baggage handling, stronger fleet reliability and further runway in TechOps. He said MRO revenues are still on track for roughly $1.2 billion this year, up nearly 50% from last year, with low-double-digit margins.
Delta’s Tone Stays Firm on the Back HalfThe call’s tone was confident but disciplined. Management did not present the quarter as a peak condition. Instead, executives repeatedly pointed to modest capacity, better unit revenue trends, cost normalization and stronger cash generation as the foundation for second-half earnings growth.
That framing left investors with a company focused on preserving pricing, expanding high-margin revenue streams and keeping leverage moving lower while still investing in product, technology and operations.
Zacks Signals for DALDAL carries a Zacks Rank #3 (Hold), along with a Value Score of A, Growth Score of C, Momentum Score of A and VGM Score of A. Within the Zacks framework, stronger Style Scores indicate more favorable value, growth or momentum characteristics, while the VGM score reflects a blended view across all three. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
A Zacks Rank #3 does not carry the same upside signal as a Zacks Rank #1 (Strong Buy) or 2 (Buy), even with strong Style Scores. The current mix points to attractive value and momentum traits, but the Zacks Rank can change as earnings estimate revisions adjust after the quarter.
EUR/USD slábne, protože napětí mezi USA a Íránem zvyšuje poptávku po dolaru a tlačí výnosy amerických dluhopisů výš. Trh teď sleduje CPI v USA; nad 1,1370 je podpora, pod ní leží 1,1350.
EUR/USD has slipped as renewed US-Iran tensions strengthened safe-haven demand for the US dollar and pushed Treasury yields higher. A break below 1.1370 could expose the pair to 1.1350 and 1.1300, while recovery attempts remain capped near the 1.1475 to 1.1500 area. US inflation data is the next major catalyst, with a hotter CPI reading likely to reinforce dollar strength and increase pressure on the euro. EUR/USD came under renewed selling pressure on Monday as fresh military exchanges between the United States and Iran revived demand for the US dollar and lifted global energy prices.
The pair struggled to build on last week’s recovery and moved back toward the lower end of its recent range as investors prepared for the latest US Consumer Price Index report. Higher crude oil prices have added to inflation concerns, pushing US Treasury yields higher and strengthening expectations that the Federal Reserve may keep interest rates restrictive for longer.
The Dollar Index has recovered toward the 101.00 area after ending the previous week lower. For EUR/USD, the stronger greenback has brought the 1.1370 support level back into focus, with traders assessing whether the pair can stabilize or extend its decline toward 1.1350 and 1.1300.
Why Is EUR/USD Falling Today? The latest weakness in EUR/USD reflects a combination of geopolitical risk, higher oil prices and rising US bond yields.
Fresh attacks between the US and Iran over the weekend raised concerns about the future of shipping through the Strait of Hormuz. Iran said the key waterway had been closed again, while Washington maintained that commercial traffic could continue.
The conflicting claims sent crude oil prices sharply higher and revived concerns that another energy shock could keep global inflation elevated.
Higher oil prices tend to support the US dollar during periods of market stress. They can also place additional pressure on the euro because the Eurozone relies heavily on imported energy, leaving the region more exposed to rising fuel costs.
US CPI Could Decide the Dollar’s Next Move The US inflation report is likely to become the most important driver for EUR/USD in the near term.
A stronger-than-expected CPI reading would reinforce expectations that the Federal Reserve may need to maintain higher interest rates or consider additional tightening later this year. That outcome would likely push Treasury yields and the dollar higher, increasing the risk of EUR/USD falling through its current support zone.
A softer inflation report would create a different setup. It could reduce pressure on the Fed to tighten policy further and allow EUR/USD to recover some of its recent losses.
However, the impact of softer inflation could be limited if oil prices continue rising or geopolitical tensions worsen.
Euro Recovery Struggles Near 1.1500 EUR/USD recently recovered from lows around 1.1325 and moved above 1.1420, but the advance stalled before the pair could establish a sustained move through the 1.1475 to 1.1500 region.
That failure suggests sellers remain active whenever the euro approaches higher levels.
The pair now faces an important test around 1.1370. A clear move below that level would increase the likelihood of a decline toward 1.1350, followed by the June low near 1.1325. If selling pressure persists, the psychological 1.1300 level could become the next target.
On the upside, EUR/USD would need to recover above 1.1450 before challenging 1.1475 and 1.1500 again. A sustained break through 1.1500 would weaken the immediate bearish outlook and could support a broader recovery toward 1.1580.
ECB and Fed Policy Expectations Remain Divided Interest-rate expectations on both sides of the Atlantic continue to shape the EUR/USD outlook.
The Federal Reserve remains focused on inflation after stronger energy prices complicated the outlook for consumer prices. Recent weakness in US employment reduced expectations of immediate tightening, but the latest geopolitical escalation has prevented markets from fully dismissing the possibility of another rate increase.
In Europe, softer core inflation has reduced expectations of further European Central Bank tightening. That leaves the euro with less policy support, particularly if US inflation remains elevated and Treasury yields continue climbing.
Comments from Federal Reserve and ECB officials will therefore remain important as traders look for any change in the policy outlook.
EUR/USD Outlook The near-term EUR/USD price forecast remains cautious as the pair struggles to hold its recent recovery.
The US dollar is benefiting from safe-haven demand, rising oil prices and higher Treasury yields, while the euro faces renewed pressure from Europe’s exposure to imported energy costs.
A break below 1.1370 would put 1.1350 and 1.1300 within reach. However, softer US inflation or an easing of Middle East tensions could weaken the dollar and help EUR/USD return toward 1.1450 and 1.1500.
For now, US CPI and developments surrounding the Strait of Hormuz are likely to determine whether the pair stabilizes or begins another leg lower.
Why is EUR/USD falling today?
EUR/USD is falling as renewed US-Iran tensions increase safe-haven demand for the US dollar. Rising oil prices and Treasury yields have also strengthened expectations that US interest rates may remain elevated.
What are the key EUR/USD levels to watch?
The main support levels are 1.1370, 1.1350 and 1.1300. Resistance is located near 1.1450, followed by 1.1475 and 1.1500.
How could US CPI affect EUR/USD?
A hotter US CPI reading could strengthen the dollar and push EUR/USD lower by increasing expectations of tighter Federal Reserve policy. Softer inflation could weaken the greenback and support a euro recovery.
Incyte uvedla, že latarcibart v malé studii u von Willebrandovy choroby snížil medián roční míry krvácení o 81 % napříč všemi typy onemocnění. Léčba byla také dobře snášena a nyní se testuje v pivotální fázi 3 VIVID-6.
- Treatment with latarcibart led to an 81% median reduction in annualized bleeding rate (ABR) across all bleeding categories and patient types with von Willebrand disease (VWD)
- Latarcibart, administered via a once monthly subcutaneous dosing regimen, was shown to be safe and well tolerated over multiple doses in this study
- Pivotal Phase 3 VIVID-6 trial evaluating latarcibart’s potential to be the first targeted therapy for VWD is currently enrolling
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) today announced complete safety and efficacy data from all patients (n=16) enrolled in the Phase 1/2 multidose study of VGA039 (latarcibart), a novel, Protein S-targeting, investigational monoclonal antibody for patients with von Willebrand disease (VWD). The data are being shared in an oral presentation today at the 34th Congress of the International Society on Thrombosis and Haemostasis (ISTH 2026 Congress) in Paris.
“These results continue to build a highly consistent body of evidence supporting latarcibart as a significant potential treatment advancement for patients with VWD,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of R&D.
Share Latarcibart modulates Protein S to improve hemostasis, potentially enhancing the body’s ability to prevent or reduce the frequency of bleeding episodes. Latarcibart is in pivotal Phase 3 development for patients with VWD, the most common inherited bleeding disorder. If approved, latarcibart has the potential to be the first, once monthly subcutaneous prophylactic therapy for patients with VWD, offering an important alternative to the frequent intravenous infusions of replacement factor concentrates commonly used in the prophylactic setting today. Given its novel mechanism, latarcibart may also have potential in other bleeding disorders.
“These results continue to build a highly consistent body of evidence supporting latarcibart as a significant potential treatment advancement for patients with VWD,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. “This multidose dataset underscores the potential of latarcibart to address the longstanding need for a prophylactic therapy that provides meaningful protection for patients with all types of VWD. We are continuing to enroll the Phase 3 VIVID-6 study as we work toward redefining the standard of routine prophylactic care for patients with VWD.”
As of May 5, 2026, data from all 16 patients enrolled in the Phase 1/2 multidose study were available, and all participants had completed the multidose regimen of six doses of latarcibart, with maintenance doses administered subcutaneously every four weeks. Key data highlights include:
Substantial reductions in ABR (annualized bleeding rate) were seen across study patients, including all VWD types and bleed types, such as serious GI and hemophilia-like joint and muscle bleeds. The median ABR reduction across all VWD types and bleed categories was 81%. In patients switching from prior von Willebrand factor (VWF)-containing prophylaxis (IV infusions multiple times per week), bleed reductions were 75-100%, indicating potential improvement over current standard of care. Among patients not previously receiving IV prophylaxis, 7 had historical ABRs >12, a key eligibility criterion for the Phase 3 VIVID-6 study. In this group, ABR reductions ranged from 46-100%, with nearly all patients (6/7) achieving reductions >73%. Latarcibart treatment resulted in ~86% reduction in VWF-treated breakthrough bleeds, with 70% of patients with prior VWF-treated bleeds not experiencing a VWF-treated breakthrough bleed while on treatment. All participants who entered the study with a substantial bleed burden transitioned to continue receiving latarcibart in the ongoing open-label extension study. Latarcibart once monthly subcutaneous prophylaxis was safe and well tolerated over multiple doses. Three treatment-emergent adverse events (TEAEs) related to latarcibart were reported: two Grade 2 headaches in one patient and one report of Grade 1 injection site reactions. There was also one unrelated serious adverse event of severe gastrointestinal (GI) bleeding in a patient with a history of frequent and severe GI bleeding. “Many people with VWD struggle with bleeding and need more effective and convenient prophylactic treatments. The study results showed treatment with latarcibart delivered consistent and clinically meaningful reductions in bleeding across a diverse group of VWD patients, including patients with all major types of the disease and individuals transitioning from intensive IV prophylaxis,” said Allison Wheeler, M.D., MSCI, Associate Professor of Pediatrics at the University of Washington. “Equally important, the favorable safety profile and once monthly subcutaneous dosing regimen have the potential to substantially reduce treatment burden while providing consistent bleed protection. Together, these findings provide a strong foundation for the Phase 3 study and support latarcibart’s potential as an important new treatment option for patients with VWD.”
More information regarding the ISTH 2026 Congress can be found on the ISTH website: https://www.isthcongress.org/ (Session details: Novel Therapies for Bleeding Disorders, Including VWD and Rare Bleeding Disorders – 2; Publication Number: OC 32.3).
About VGA039 (latarcibart)
VGA039 (latarcibart) is an investigational monoclonal antibody therapy with a novel mechanism of action that targets Protein S, with dual actions promoting platelet attachment and enhancing fibrin deposition to restore hemostasis. Latarcibart has the potential to be a universal prophylactic therapy for numerous bleeding disorders, starting with all types of von Willebrand disease (VWD) and bleeding sites. As a subcutaneously self-administered investigational antibody therapy with a once monthly dosing regimen, latarcibart has the potential to improve bleeding outcomes, convenience, and quality of life for patients.
Latarcibart has received Breakthrough Therapy, Fast Track, orphan drug and rare pediatric disease designations from the U.S. Food and Drug Administration (FDA). Latarcibart has advanced into the Phase 3 VIVID-6 study (NCT07115004), a global single arm cross-over study to investigate safety and efficacy of the subcutaneous administration of latarcibart as prophylaxis for bleeding in patients with every type of VWD, including those with a high disease burden.
Incyte acquired VGA039 (latarcibart) in July 2026 as part of its acquisition of Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics LLC.
About the VIVID Clinical Program
The VIVID multinational clinical program consists of multiple clinical trials, from Phase 1 to 3, in both a platform multi-phase protocol (VIVID-1-5) and a standalone Phase 3 protocol (VIVID-6) evaluating the safety and efficacy of VGA039 in VWD. The VIVID clinical program is active across 6 continents and designed to support future registrational filings globally.
About von Willebrand Disease
Von Willebrand disease (VWD) is the most common inherited bleeding disorder in which the blood does not clot properly, caused by low or defective von Willebrand factor (VWF). People with VWD may experience excessive bleeding with varying severity and frequency, negatively impacting their daily lives. Current therapies for VWD prophylaxis include factor replacement therapies requiring multiple intravenous (IV) infusions every week. Approximately 135,000 people in the United States have been diagnosed with von Willebrand disease.1
About Incyte®
Incyte is redefining what’s possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless focus on patients, we have built an established portfolio of first-in-class medicines and an extensive portfolio of next-generation medicines across our key franchises: Hematology, Oncology and Inflammation & Autoimmunity.
To learn more, visit Incyte.com and Investor.Incyte.com. Follow us on social media: LinkedIn, X and Instagram.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the data to be presented by Incyte at the ISTH 2026 Congress; Incyte’s expectations regarding VGA039’s (latarcibart’s) clinical development and regulatory approvals; the potential and promise latarcibart offers patients with bleeding disorders, including the potential to be the first once monthly subcutaneous prophylactic therapy for patients with VWD, its potential improvement over current standards of care for patients with VWD and other bleeding disorders, and its potential ability to address significant unmet need, reduce treatment burden and improve quality of life; and Incyte’s aspirations and goals as set forth under the heading “About Incyte.”
Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including results from clinical trials of and the sufficiency of clinical trial data for latarcibart, as well as Incyte’s other products and product candidates, to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; Incyte’s ability to achieve commercial success for latarcibart, if approved; Incyte’s ability to obtain and maintain protection of intellectual property for its products and technology; Incyte’s reliance on third parties and partners; the acceptance of Incyte’s products in the marketplace; market competition, sales, marketing, manufacturing and distribution requirements; and those risks and uncertainties discussed in greater detail in Incyte’s reports filed with the U.S. Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2025 and its quarterly report on Form 10-Q for the quarter ended March 31, 2026. Incyte disclaims any intent or obligation to update these forward-looking statements.
GBP/AUD začíná týden poblíž pětiměsíčních maxim kolem 1,9271. Trh sleduje britský měsíční odhad HDP za květen a čínský HDP za 2. čtvrtletí spolu s červnovými daty, která mohou určit další směr páru.
The Pound to Australian Dollar (GBP/AUD) exchange rate opens the new week around 1.9271 after holding close to five-month highs, with Sterling remaining well supported while the Australian Dollar faces another busy week of domestic data and renewed scrutiny over China's economic outlook.
Latest — Exchange Rates:
Pound to Australian Dollar (GBP/AUD): 1.927065 (-0.05%)
Pound to Dollar (GBP/USD): 1.339 (-0.12%)
Australian Dollar to Dollar (AUD/USD): 0.694839 (-0.07%)
WEEKLY RECAP:
GBP/AUD spent much of last week consolidating just below the 1.93 level after a strong rally through June.
The Pound continued to outperform despite evidence that the UK economy is slowing.
Markets remain reluctant to price aggressive Bank of England easing while inflation stays above target, helping Sterling retain a yield advantage over several major currencies.
In its latest monthly outlook, MUFG said the Pound was among the strongest-performing G10 currencies through June, supported by resilient investor confidence and the fading inflation shock as oil prices retreated.
The Australian Dollar struggled to generate sustained demand.
Although global risk sentiment has improved following the easing of Middle East tensions, investors remain cautious over China's economic outlook, a key driver for Australian exports.
Reuters has reported that attention is now turning to China's second-quarter GDP and June activity data, with markets expecting slower growth after softer domestic demand and weaker investment. Those figures are likely to have an important bearing on the Australian Dollar this week.
In a recent client note, ING highlighted that Sterling is increasingly being driven by domestic developments, while commodity-linked currencies remain more exposed to changes in global growth expectations.
Near-Term GBP/AUD Forecast: China GDP and UK GDP in Focus For Pound Sterling, investors will watch Thursday's monthly UK GDP estimate for May, together with industrial production and trade balance figures. Stronger-than-expected data would reinforce the view that the UK economy has remained resilient despite softer business surveys.
For the Australian Dollar, the spotlight falls on China's second-quarter GDP, June retail sales and industrial production, all due on Wednesday. Stronger Chinese data would likely support the Australian Dollar by improving confidence in Australia's export outlook, while weaker figures could renew pressure on the currency.
Markets will also continue to monitor developments in commodity markets following the recent decline in oil prices and any fresh guidance from Reserve Bank of Australia officials after last week's policy decision.
If UK GDP surprises to the upside while Chinese growth data disappoints, GBP/AUD could retest resistance around 1.94.
However, stronger Chinese activity data and firmer commodity prices could allow the Australian Dollar to recover, pulling the pair back towards 1.90.
SK Hynix na domácím trhu v Soulu zažil nejhorší den v historii, když jeho akcie spadly o více než 15 %. Výprodej přišel jen pár dní po úspěšném debutu ADR v USA, kde akcie v pátek posílily o 13 %.
Akcie jihokorejského výrobce paměťových čipů SK Hynix kótované na domácím trhu v Soulu zaznamenaly na začátku nového týdne nejhorší denní propad ve své historii, když klesly o více než 15 procent. Pondělní výprodej zasáhl celý jihokorejský trh. Třeba konkurenční Samsung Electronics ztratil bezmála 11 procent a hlavní index Kospi se propadl zhruba o devět procent.
K pádu SK Hynix došlo jen pár dní poté, co společnost vstoupila na americký trh prostřednictvím ADR, kde při svém pátečním debutu akcie posílily o 13 procent.
„Vstup na burzu ADR byl velmi úspěšný, ale velká část tohoto úspěchu již byla započítaná. Dnešní slabost zřejmě odráží typickou reakci ‚sell the news‘ a realizaci zisků spíše než jakoukoliv změnu fundamentálních ukazatelů,“ řekl agentuře Bloomberg Chan H. Lee, řídící partner hedgeového fondu Petra Capital Management v Soulu.
Nabídka akcií SK Hynix v hodnotě 26,5 miliardy dolarů byla investory i analytiky vnímána jako důležitý test chuti trhu financovat velké zahraniční emise a zároveň jako prověrka odolnosti současné AI rally. Navzdory rostoucím debatám o vysokých valuacích technologických titulů a enormních investicích do AI byla emise podle informací z trhu více než sedminásobně přeupsána.
SK Hynix se v posledních letech stal jedním z klíčových hráčů v dodavatelském řetězci AI díky dominantní pozici na trhu s HBM pamětmi (High Bandwidth Memory), které se používají v nejvýkonnějších AI akcelerátorech od Nvidie. Prudce rostoucí poptávka po těchto čipech pomohla firmě k rekordním ziskům, přičemž její akcie během posledních 12 měsíců vzrostly o více než 500 procent, připomíná Bloomberg.
Analytici z Korea Investment & Securities upozorňují, že provozní zisk SK Hynix za poslední čtvrtletí by mohl zaostat za tržním konsensem přibližně o osm procent. Důvodem je mimo jiné struktura tržeb firmy. Významný podíl pochází právě z HBM pamětí, jejichž ceny sice rostou, avšak pomaleji než u některých tradičních typů paměťových čipů. Kontrakty na dodávky HBM bývají často uzavírány na delší období a poskytují menší prostor pro rychlé promítnutí tržních cenových změn.
Na druhé straně vedení společnosti nadále zdůrazňuje, že globální nedostatek pamětí by mohl přetrvávat ještě řadu let. Generální ředitel SK Hynix Kwak Noh-Jung v nedávném rozhovoru uvedl, že napjatá situace na trhu nemusí skončit ani po roce 2030.
Od červnového historického maxima už každopádně akcie odepsaly přes 35 procent. Technické ukazatele přitom naznačují, že na titulu došlo z přehřátých úrovní z počátku tohoto roku k ochlazení. „Ještě jeden týden poklesu je možný, ale vnímáme to jako příležitost k dalšímu nákupu. Rally v Koreji by měla ADR vytlačit výše. Takže je to dobrá pozice k nákupu,“ uvedl Nico Rosti, analytik společnosti MRM Research.
Volatilita na korejské burze narůstá
Úspěch firem napojených na boom AI výrazně změnil dynamiku jihokorejského akciového trhu. Investoři, zejména ti drobní, ve velkém směřují kapitál právě do SK Hynix a Samsungu, což zvyšuje volatilitu.
K prudkým pohybům přispívá také popularita pákových ETF fondů navázaných na akcie obou výrobců pamětí. Výsledkem jsou mimořádně výrazné denní výkyvy indexu Kospi, který letos zažil již sedm obchodních přerušení kvůli extrémnímu pohybu trhu. Přitom od roku 2000 se takový zásah ze strany regulátorů uskutečnil pouze 13krát.
Rostoucí citlivost trhu se projevila i minulý týden po zveřejnění předběžných výsledků Samsungu. Přestože firma zůstává jedním z hlavních beneficientů AI trendu, investoři reagovali prodeji, které následně zasáhly širší technologický sektor.
Intuitive Surgical má ve 2. čtvrtletí vykázat zisk 2,50 USD na akcii a tržby 2,82 miliardy USD, což je více než loni. Akcie v pátek klesly o 1,2 % na 406,78 USD.
Intuitive Surgical, Inc. (NASDAQ:ISRG) will release its second quarter earnings report after the closing bell on Thursday, July 16.
Analysts expect the Sunnyvale, California-based company to report quarterly earnings of $2.50 per share, up from $2.19 per share in the year-ago period. The consensus estimate for Intuitive Surgical’s quarterly revenue is $2.82 billion. It reported $2.44 billion last year, according to Benzinga Pro.
On May 28, Intuitive announced the promotion of global senior vice president of Intuitive’s endoluminal business Taylor Patton to chief commercial and marketing officer.
Intuitive Surgical shares fell 1.2% to close at $406.78 on Friday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.
Considering buying ISRG stock? Here’s what analysts think:
Photo via Shutterstock
Market News and Data brought to you by Benzinga APIs
TSMC oznámila ve 2. čtvrtletí rekordní tržby ve výši 1,27 bilionu NT$ po meziročním růstu o 36 %, nad odhady trhu. Tahounem byl silný zájem o aplikace umělé inteligence.
The TSMC logo in this illustration taken June 11, 2026. REUTERS/Dado Ruvic/Illustration Purchase Licensing Rights, opens new tab
TAIPEI, July 13 (Reuters) - TSMC, the world's largest contract chipmaker, reported on Monday second-quarter revenue that rose 36% from a year earlier to a record high on surging interest in artificial intelligence applications.
Revenue in the April-June period of this year came in at T$1.27 trillion ($39.62 billion), according to Reuters calculations, slightly above a T$1.264 trillion LSEG SmartEstimate drawn from 20 analysts.
Make sense of global markets with the Trading Day newsletter. Sign up here.
Taiwan Semiconductor Manufacturing Co (TSMC) (2330.TW), opens new tab, is a major supplier to companies including Nvidia (NVDA.O), opens new tab and Apple (AAPL.O), opens new tab.
On its last earnings call in April, the company predicted second-quarter revenue of between $39 billion and $40.2 billion. The company gives its forecast only in U.S. dollars and not Taiwan dollars.
For June alone, TSMC reported that revenue rose 67.9% year-on-year to T$442.68 billion, which was up 6.2% compared with the previous month.
The data was originally due last Friday, but it was delayed due to the impending arrival of Typhoon Bavi, which shut financial markets in Taipei that day.
TSMC, Asia's most valuable publicly listed company with a market capitalisation of $1.955 trillion, did not provide any details or forward guidance in its brief revenue statement.
It is scheduled to report second-quarter earnings on Thursday, when it will also update its outlook and plans for the current quarter and the rest of the year.
TSMC is expected to report a 58.8% on-year rise in second-quarter net profit, according to an LSEG SmartEstimate.
TSMC's Taipei-listed shares closed up 1% on Monday ahead of the release of the sales data. The broader market (.TWII), opens new tab closed flat.
The company's shares have risen 57% so far this year, in line with the broader market.
($1 = 32.0530 Taiwan dollars)
Reporting by Wen-Yee Lee and Ben Blanchard; Editing by Thomas Derpinghaus and Jamie Freed
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Taiwan Semiconductor Manufacturing Co. reported a 67.9% year-on-year rise in its June sales on Monday, ahead of its second-quarter earnings release later this week.
For the first half of 2026, TSMC's total revenue reached 2.4 trillion new Taiwan dollars ($74.99 billion), representing a 35.6% increase compared to the same period in 2025. TSMC reported June revenue of NT$ 442.68 billion — a 6.2% increase from the previous month.
The Taiwanese chip giant's shares were trading 1% higher Monday.
The company' growth has been boosted by demand for artificial intelligence chips and infrastructure investments.
The world's largest contract chipmaker manufactures semiconductors for a wide range of applications, spanning from smartphones to high-performance AI computing systems, with key clients including U.S. technology leaders such as AI darling Nvidia, Apple and Advanced Micro Devices.
TSMC plans to add two advanced chip packaging plants in the Chiayi Science Park in southern Taiwan, Reuters reported, citing remarks made by Taiwan's National Science and Technology Council Minister Wu Cheng-wen on Sunday. Wu noted that the site's first facility is already in mass production, with the second expected to begin shortly.
TSMC, which commands a 73% share of the global pure-foundry market — chips manufactured for clients — in the first quarter of 2026, according to data from Counterpoint Research, is set to report its second-quarter earnings on Thursday, July 16.
Americké spotové Bitcoin ETF zaznamenaly za týden čistý příliv 197,4 mil. USD a ukončily osm týdnů trvající sérii odlivů. Nejvíc přidal BlackRock iShares Bitcoin Trust ETF s přílivem 291,9 mil. USD.
US-listed spot Bitcoin exchange-traded funds recorded a net inflow of $197.4 million in the week ended Friday, snapping an eight-week streak of weekly outflows dating back to May.
Data from Farside Investors shows that most of the week’s gains came from the BlackRock iShares Bitcoin Trust ETF, which recorded $291.9 million in inflows. This was offset by outflows from the Grayscale Bitcoin Trust ETF, the Fidelity Wise Origin Bitcoin Fund and the ARK 21 Shares Bitcoin ETF.
The end of the outflow streak could suggest institutional demand for Bitcoin is recovering after two months of sustained selling pressure. However, analysts say it’s too early to tell.
“While one week of inflows doesn’t define a trend, it comes at a time when institutional confidence is growing around the potential passage of the CLARITY Act in the US in August next month,” Monochrome Asset Management founder and CEO Jeff Yew told Cointelegraph.
“This could be an early indication that institutions are beginning to position ahead of greater regulatory certainty, which is often what long-term capital allocators look for.”Meanwhile, 10x Research founder and CEO Markus Thielen said ETF and stablecoin outflows and seasonality in August and September remain headwinds.
“There's also been a pattern over the past few months where Bitcoin performs better in the first half of the month, then consolidates in the latter half. Without flows still pronounced and ETF flows yet to meaningfully pick up, even after Bitcoin's 9%+ jump, the headwinds remain in our view.”
The $197.4 million weekly inflow was modest compared with the $8.26 billion investors withdrew since May 11.
Total spot Bitcoin ETF net inflow. Source: SoSoValue
Last week, Real Vision chief crypto analyst Jamie Coutts told Cointelegraph that Bitcoin could be entering the latter stages of the bear market, based on early technical signs suggesting that selling pressure is easing.
“I think we're getting through most of the bear market action. It's still not over, clearly. But you know, I think we're approaching at least the second half,” Coutts said.
Other analysts say there could be further downsides ahead.
Russell Thompson, chief investment officer at asset manager Hilbert Capital told Cointelegraph last week that he believes Bitcoin remains in a downcycle and could hit a low around October this year.
Ether ETFs also break outflow streakMeanwhile, US-listed spot Ether ETFs also broke their eight-week losing streak, with $84.42 million in net inflows for the week ended Friday, led by BlackRock and Fidelity’s Ether funds.
The inflows paled in comparison with the $1.2 billion in net outflows since May 11.
Magazine: Has Bitcoin bottomed for this cycle? Analysts say 'not yet'
Cointelegraph is committed to independent, transparent journalism. This news article is produced in accordance with Cointelegraph’s Editorial Policy and aims to provide accurate and timely information. Readers are encouraged to verify information independently.
PepsiCo po slabších výsledcích za 2. čtvrtletí potvrdila celoroční výhled a zvýšila dividendu už 54. rokem v řadě. Akcie se obchodují poblíž 52týdenního minima a nesou asi 4,3% výnos.
The first half of 2026 belonged to artificial intelligence. The second half, so far, has belonged to almost everything else.
In the opening stretch of July, technology has been the market's worst-performing sector. Meanwhile, cash has flowed into the corners investors ignored all year: energy, financials, healthcare, and consumer staples. A soft June jobs report, which showed the economy adding just 57,000 jobs, cooled bets on a Federal Reserve rate hike and gave the rotation a further push.
For income investors, I think a rotation into defensive, dividend-paying stocks is worth a closer look. Three names in particular stand out.
Each is a Dividend King with at least half a century of consecutive annual increases, and each sits at a very different point in this trade. Here's a look at Coca-Cola, Johnson & Johnson, and PepsiCo.
Image source: Getty Images.
1. Coca-Cola: quality, already rewarded Coca-Cola (KO +1.05%) is what the rotation looks like when it works. The beverage giant trades near an all-time high, and the business has earned it. First-quarter organic revenue rose 10% year over year, a strong result for a company this size and this old.
The dividend, of course, is about as secure as dividends get. Coca-Cola has raised its payout for 64 straight years, and the current $2.12 annual dividend uses up only about two-thirds of earnings.
Today's Change
(
1.05
%) $
0.87
Current Price
$
83.50
The one drawback is the price -- at roughly 25 times forward earnings, with a 2.5% yield, Coca-Cola is arguably priced like the defensive stalwart it is. You're buying quality here, but you're not buying it cheap.
2. Johnson & Johnson: the healthcare anchor Johnson & Johnson (JNJ 0.82%) offers a similar kind of durability from a different sector. The healthcare giant just raised its dividend for the 64th consecutive year, matching Coca-Cola for the longest streak of this trio.
Indeed, its first-quarter results gave the increase plenty of cover. Revenue rose about 10% year over year, adjusted earnings per share came to $2.70, and management lifted its full-year outlook to about $11.55 in adjusted earnings per share, helped by strong demand for cancer drug Darzalex and immunology treatment Tremfya.
Today's Change
(
-0.82
%) $
-2.12
Current Price
$
256.98
At about 22 times forward earnings and a 2.1% yield, Johnson & Johnson sits between its two peers here on valuation, though its yield is the lowest of the three. Its dividend consumes less than half of adjusted earnings, so there's ample room for more increases. Investors will get a fresh read soon, too: the company reports second-quarter results this week, on July 15.
3. PepsiCo: the cheap, out-of-favor one If Coca-Cola is the rotation's winner, PepsiCo (PEP 0.35%) is the name it has passed by so far. The snacks and beverages maker trades near a 52-week low.
Its second-quarter report on Thursday explains part of why. Organic revenue grew just 2.4%, in line with the sluggish low-single-digit pace of recent quarters, and volume in its North American beverage business fell 4%.
But there's another side to this. PepsiCo affirmed its full-year outlook, still expects core constant currency earnings per share to grow 4% to 6% for the year, and just raised its dividend for the 54th year running.
Today's Change
(
-0.35
%) $
-0.48
Current Price
$
137.38
After the sell-off, the stock now yields about 4.3% -- comfortably the highest of the three -- at roughly 16 times forward earnings, easily the cheapest. For investors who think the rotation into unloved value has further to run, that's arguably the most direct way to play it in this group.
The better way to play the rotation? So which of these three fits the moment best? It depends on what an investor is after.
The highest quality, for those willing to pay up, is Coca-Cola. The steadiest, and the one giving a fresh read on its business next, on July 15, is Johnson & Johnson. And the best value, for anyone willing to sit through some near-term softness, is PepsiCo.
Personally, in a rotation like this, I lean toward the cheapest, most out-of-favor name, which points to PepsiCo. Its U.S. business isn't at its strongest right now, but a 4.3% yield backed by 54 years of increases pays investors well to be patient.
Of course, none of these is a bargain in absolute terms. And a market that turns back toward growth could leave defensive payers behind just as fast as it found them. But if the rotation into value has staying power, these three sit squarely in its path.
TSMC přidá v Chiayi Science Park dvě další pokročilé závody na pouzdření čipů. Park má po spuštění všech čtyř továren dosáhnout roční produkce přes 300 miliard TWD a vytvořit více než 9 000 pracovních míst.
A general view of the Taiwan Semiconductor Manufacturing Company's (TSMC) fabrication plant in Kaohsiung, Taiwan, June 7, 2025. REUTERS/Ann Wang Purchase Licensing Rights, opens new tab
TAIPEI, July 13 (Reuters) - Taiwan Semiconductor Manufacturing Co (TSMC) (2330.TW), opens new tab will add two advanced chip packaging plants in the Chiayi Science Park, the island's science and technology minister said on Sunday.
Located in southern Taiwan, the Chiayi Science Park is being developed as one of TSMC's major advanced chip-packaging hubs.
Make sense of global markets with the Trading Day newsletter. Sign up here.
TSMC's first advanced chip packaging plant at the Chiayi Science Park has already entered mass production and its second plant is expected to begin mass production soon, National Science and Technology Council Minister Wu Cheng-wen said at a groundbreaking ceremony.
"Today's groundbreaking marks the start of the second phase, which will include a third and fourth plant," Wu said, adding that the park is expected to generate more than 300 billion Taiwan dollars ($9.35 billion) in annual production value and create more than 9,000 jobs once all four plants are up and running.
TSMC is rapidly expanding its advanced chip-packaging capacity, including its chip-on-wafer-on-substrate technology, as demand from artificial intelligence chip designers like Nvidia (NVDA.O), opens new tab continues to outstrip supply.
($1 = 32.0970 Taiwan dollars)
Reporting by Wen-Yee Lee; Editing by Thomas Derpinghaus
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Allium Labs našla neobvyklé obchodování se ZEC před odhalením chyby v Orchard, což vyvolalo podezření na obchodování na základě neveřejných informací. Největší short za 34,5 milionu USD vydělal asi 998 000 USD.
Developers recently revealed that a four-year-long vulnerability in Orchard may have enabled unlimited counterfeit Zcash [ZEC] until an emergency patch was issued. However, fresh market data has raised further questions regarding events before the discovery.
Allium Labs, after reviewing trade history, identified unusual trading activity. On the 26th of May, ZEC’s trading volume surged 12–13 times above its average. Researchers privately uncovered the defect three days later, on the 29th of May.
Source: Allium Research While researchers were identifying the defect, ZEC declined from approximately $660 down to $530, indicating increasing selling pressure. The developers disabled Orchard on the 2nd of June and issued a patch on the 3rd of June, yet confidence continued fading.
By the 5th of June, ZEC had fallen by 64 percent from $685 to $247 with hourly trading at $560 million.
Early positioning fuels market suspicion The uncertainty in the aftermath of this issue also led to further review of which parties were actively trading in the market ahead of the issue becoming apparent. Allium found that traders opened the most profitable positions on the 25th and 26th of May.
This occurred days before the private discovery of the Orchard flaw. More importantly, traders opened these large positions before researchers privately disclosed the flaw on the 29th of May. Notably, the largest wallet had a short position worth $34.5 million and, as a result, made approximately $998,000 in profits.
Source: Allium Research A second short position worth $17.7 million accrued profits of approximately $724,000. These high profits raised questions about whether traders anticipated the sell‑off.
However, the data does not provide sufficient evidence to prove such claims. In futures markets, all shorts are offset by an equal number of longs. Therefore, simply showing profitable positions is insufficient to establish that those positions existed due to prior knowledge.
That balance became evident when the largest $91.5 million long position ultimately lost $6.97 million. Meanwhile, Zcash’s privacy model prevents anyone from verifying whether the flaw was ever exploited. This left markets to price on probabilities instead of certainty and kept confidence fragile despite the completed patch.
Final Summary Allium Labs flagged unusual ZEC trading before the Orchard flaw discovery, fueling suspicion of informed positioning. Profitable shorts raised questions, but lack of evidence and Zcash privacy kept confidence fragile.
Aave Labs spustila Stable Vaults, které firmám umožňují integrovat fixní výnosy ze stablecoinů bez vlastní infrastruktury. Řešení převádí kolísavé on-chain sazby na stabilní sazby a podporuje i více řetězců.
Aave Labs has rolled out Stable Vaults, a platform that enables organizations to easily incorporate fixed-rate stablecoin returns into their offerings. These smart contract vaults, which currently support the Aave mobile savings application, are now open for any business to integrate and customize. This launch marks an important advancement in bridging decentralized finance with everyday financial products.
In the past, adding DeFi yields to consumer applications required handling unpredictable interest rates, liquidity spread across various blockchains, and complex infrastructure layers connecting on-chain strategies to end users.
Drawing on years of experience tackling these issues, Aave Labs developed Stable Vaults as a streamlined answer.
The system converts fluctuating lending rates from on-chain markets into consistent fixed rates that companies can confidently advertise.
It also simplifies critical processes such as portfolio adjustments, operations spanning multiple chains, and accurate payout calculations for customers.
As a result, any enterprise can now tap into Aave-powered yields or alternative ERC-4626 compliant strategies without constructing the entire yield management system internally.
Stable Vaults function as a complete backend solution for generating on-chain stablecoin income.
Businesses retain authority over the stablecoins they accept, the yield approaches they deploy, and the specific fixed rates provided to individual users.
For instance, neobanks can embed reliable savings features powered by Aave markets directly within their applications.
Payment service providers might allow merchants to generate returns on funds sitting idle between transfers using dedicated vaults.
Wallet operators and trading platforms can introduce effortless one-click earning options supported by products like Savings GHO, bypassing the need to manage underlying infrastructure.
Similarly, fintech companies launching their own stablecoins can register them as viable assets to build enclosed earning loops for their user base through tailored ERC-4626 vaults.
Operators gain additional tools to enhance user incentives, such as granting higher returns to loyal or premium customers and launching short-term rate promotions.
Returns exceeding these commitments flow back to the business as additional revenue.
Since the deploying entity selects the assets and strategies, each implementation can be fine-tuned to align with unique product needs, local regulations, or preferred risk levels.
The technology addresses several longstanding technical obstacles at once, from managing rate variability and cross-chain liquidity fragmentation to smoothing interactions between advanced protocols and regular users.
For customers, the integrated experience proves highly convenient as deposits immediately begin generating income upon arrival.
Individuals can move funds in or out across any networks supported by the operator and using whichever approved stablecoins are available.
Integration with services like Chainlink Price Feeds ensures dependable valuation data, while Chainlink CCIP facilitates secure transfers between chains.
The Aave App itself employs both in its operational setup, underscoring the platform’s reliability.
Positioned as a mature, live system already active in the Aave ecosystem, Stable Vaults stand ready for wider industry use.
Interested parties can consult various guides, review the publicly available code, or contact the Aave Labs team for support and further discussion. This introduction lowers the hurdles for traditional finance entities to offer competitive yields, allowing them to prioritize customer engagement and innovation while relying on proven decentralized mechanisms for consistent performance in the digital economy.
TLDR: Uniswap daily fees reached about $5.2 million in 24 hours, placing the decentralized exchange near the top of current crypto fee rankings. Robinhood Chain supplied roughly $4.38 million of the total, far exceeding Ethereum and Base during the same measured period. Only about $73,454 counted as 24-hour protocol earnings, as most swap fees still flowed to liquidity providers rather than UNI holders. Governance proposals could extend protocol fees and the UNI token burn system to v4 pools and Robinhood Chain after community approval. Uniswap daily fees reached about $5.2 million in 24 hours, placing the DEX near the top of crypto fee rankings. Founder Hayden Adams highlighted the figure on X, saying only USDC and USDT generated more fees. DefiLlama recorded $5.16 million during the same period, supporting his estimate.
Robinhood Chain supplied most of that total after launching on July 1. The sharp increase shows how quickly new networks can redirect trading activity. UNI traded near $3.62, up about 35% from its early-July low near $2.70. Yet the token still sits roughly 92% below its 2021 peak.
Uniswap Daily Fees Surge as Robinhood Chain Takes Lead Robinhood Chain contributed about $4.38 million of the reported Uniswap daily fees. Ethereum produced roughly $296,000, while Base added about $288,000. That distribution marks a sudden shift from Uniswap’s traditional Ethereum-led activity.
The Arbitrum Orbit network launched with Uniswap v2, v3, v4, and UniswapX available from day one. Cumulative swap volume crossed $1 billion by July 10, according to a Uniswap governance post. The chain also recorded a 24-hour Uniswap volume peak near $500 million during its first week.
Across seven days, Robinhood Chain generated $10.98 million of Uniswap’s $20.1 million in total fees. That share made the new network Uniswap’s largest short-term fee source. It also placed Robinhood Chain above Ethereum and Base during the measured period. The fee spike shows how concentrated short-term trading activity can become.
Uniswap daily fees reflect charges paid through swaps, but they do not equal protocol income. DefiLlama listed only $73,454 in 24-hour earnings for Uniswap. Most trading fees still flow to liquidity providers instead of the treasury or UNI holders.
The distinction matters when comparing Uniswap with stablecoin issuers or centralized exchanges. Annualizing one strong day would imply almost $1.9 billion in fees. Still, that calculation does not show how much value the protocol retains.
UNI Burn Vote Tests the Value of Rising Protocol Activity Uniswap governance is now considering a wider protocol fee rollout. One proposal would activate fees across v4 pools on several supported networks. Another would extend fee collection and UNI burns to Robinhood Chain.
The Robinhood Chain temperature check runs from July 10 through July 15. It covers v2, v3, and v4 deployments on the network. On-chain votes would follow if the Snapshot proposals pass.
Under the UNIfication system, collected protocol fees move into TokenJar contracts. Searchers can claim those assets after supplying UNI of equivalent value for burning. The process permanently removes the submitted UNI from circulation.
Higher Uniswap daily fees could expand the amount available for this mechanism. Yet liquidity providers may receive slightly lower returns when protocol fees activate. That trade-off could influence where they place capital across competing pools.
Uniswap v4 adds programmable hooks that let developers customize pool logic. These tools support dynamic fees, specialized liquidity rules, and other trading features. Wider v4 adoption could increase activity across more chains.
Circle has minted an additional $250 million of USDC on the Solana blockchain, according to a report by @martypartymusic. This issuance is part of a broader trend in 2026, where USDC minting on Solana has reached approximately $64.25 billion to $64.78 billion. The increased issuance suggests sustained demand for dollar liquidity on Solana, reinforcing its competitive position as a key settlement layer for stablecoin transactions and decentralized finance (DeFi) activities. Market participants appear to interpret this development as supportive of Solana’s price prospects, with the additional liquidity potentially influencing Solana’s ability to reach higher price targets in July.
Advertisement
Key Takeaways The $250 million USDC issuance on Solana appears to suggest continued demand for stablecoin liquidity in the network. Markets seem to view the increased liquidity as consistent with a positive outlook for Solana’s price, possibly affecting its potential to reach $90 in July. The cumulative USDC issuance on Solana for 2026 highlights its growing role in stablecoin and DeFi ecosystems. What to Watch Observers are monitoring the impact of increased USDC liquidity on Solana’s price trajectory, particularly in relation to its potential to reach the $90 mark in July. Key indicators include market responses to liquidity changes and any significant price movements. Additionally, developments in the broader crypto market and macroeconomic factors could influence Solana’s price dynamics, affecting the likelihood of reaching set targets.
Get live prediction-market analysis, powered by Vera. Sign up for Vera.
Term Structure
Contract Odds Δ since publish Volume 24h August 1 2026 20% — — View market → August 1 2026 0.5% — — View market → August 1 2026 0.1% — — View market → August 1 2026 2.4% — — View market → August 1 2026 0.9% — — View market → August 1 2026 0.8% — — View market → August 1 2026 4% — — View market → August 1 2026 0.8% — — View market → August 1 2026 13% — — View market → August 1 2026 0.1% — — View market → August 1 2026 1.8% — — View market → August 1 2026 0.1% — — View market → August 1 2026 48% — — View market →
KKR poskytne Ampolu financování ve výši A$400 milionů na refinancování a obecné firemní účely. Investice je podpořena jeho privátním úvěrovým a pojistným byznysem.
SYDNEY--(BUSINESS WIRE)--KKR, a leading global investment firm, today announced its cornerstone investment in a A$400 million (US$275 million) financing solution (the "Financing") for Ampol Limited (ASX: ALD) ("Ampol"), anchored by KKR's private credit and insurance platforms. The investment will support Ampol’s refinancing initiatives and other general corporate purposes, in line with its Capital Allocation Framework.
Listed on the ASX, Ampol operates an integrated fuel supply and marketing value chain in Australia that encompasses the Lytton refinery in Queensland, an extensive national network of terminals and pipelines, and a convenience retail footprint of approximately 1,700 sites. Ampol also maintains a significant presence in New Zealand with approximately 500 retail sites and has international operations via its trading and shipping capabilities based in Singapore and the USA.
KKR’s Asia Pacific Credit platform seeks to provide, among other private credit strategies, bespoke solutions to high-quality companies, entrepreneurs and sponsors that harness the strength of KKR’s private markets investment capabilities and its expertise as one of the largest alternative credit managers globally.
Diane Raposio, Partner and Head of Asia Credit and Markets, KKR, said, “We are focused on providing flexible capital to high-quality companies as they pursue their strategic objectives. Ampol is an established, strong investment-grade business with a long operating history and a sophisticated approach to capital management. We are pleased to partner with Ampol on this financing, building on KKR's track record in the ANZ region and across Asia Pacific.”
Greg Barnes, Group Chief Financial Officer, Ampol, said, “The transaction is another example of our proactive approach to funding and capital management. We are delighted with the significant support received from KKR on this occasion, and our collaboration with Temasek-backed Clifford Capital in arranging the transaction with our advisers. We have a meaningful presence in Singapore and value the partnership with KKR and Clifford Capital.”
KKR’s investment was supported by Clifford Capital, a Temasek-backed and Singapore-headquartered global infrastructure credit platform, reflecting the firm's capability in delivering tailored capital solutions and connecting institutional investors with leading corporates across the Asia Pacific region.
Vidyasagar Pulavarti, Chief Investment Officer, Asset Management, Clifford Capital, said, “Private investment grade credit continues to present compelling opportunities for institutional investors seeking resilient, long-term returns. We are delighted to collaborate with KKR, Ampol and Barrenjoey on this transaction, which underscores Clifford Capital Asset Management’s role as a trusted partner in accessing, structuring and delivering high-quality private credit assets, underpinned by rigorous investment discipline and robust Investment Committee oversight through our Private Investment Grade strategy.”
KKR is making this investment from its Asia Pacific Credit strategy and insurance platform. In Australia, KKR has provided bespoke solutions to Family Doctor, a leading group of general practitioner clinics, DBG Health, a leading pharmaceutical company, and Lendi, a leading fintech, and financings to companies and sponsors across a range of industries and private credit strategies. Since 2019, KKR has committed more than US$9.1 billion across 63 credit investments under its Asia Pacific Credit strategy, accounting for a total transaction volume of more than US$28.4 billion.
Disclaimer
This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for the Financing in the United States or any other jurisdiction where to do so would be unlawful. The Company has not registered, and does not intend to register, any portion of the Financing in the United States or any other jurisdiction and does not intend to conduct a public offering of securities in any of these jurisdictions.
In particular, the Financing has not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or the securities laws of any state or other jurisdiction of the United States. The Financing may not be offered or sold, directly or indirectly, in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable state securities laws. The offering is being made only to (a) persons outside of the United States or (b) "qualified institutional buyers" ("QIBs") within the meaning of Rule 144A under the Securities Act ("Rule 144A"). Prospective purchasers are hereby notified that the sellers or issuer of the Financing may be relying on the exemption from registration requirements of the Securities Act provided by Rule 144A or another available exemption from registration.
About KKR
KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR’s insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR’s investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at www.kkr.com. For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group’s website at www.globalatlantic.com.
After hitting a 52-week high of $1,255 on June 25, the Micron Technology (MU 1.05%) stock price has since retreated below $1,000. There's a likely mix of factors that have led to that decline and that are keeping the stock price from rebounding, ranging from potential profit-taking to a chip stock sell-off to increased competition from SK Hynix's listing on the Nasdaq.
In the background, however, there was a July 6 announcement from Micron that seemed to get buried.
Image source: The Motley Fool.
Micron locks in Ford On July 6, Micron Technology announced that it had entered into a long-term agreement, which it called a strategic customer agreement (SCA), with Ford to help strengthen the automaker's vehicle production. "Producing the high-volume vehicles of the future in the U.S. will require a resilient supply chain," Ford CEO Jim Farley said in the announcement.
Micron didn't offer specifics about the deal's value. But it did say the SCA was part of a collective 16 it discussed in its 2026 third-quarter earnings call.
Today's Change
(
-1.05
%) $
-10.39
Current Price
$
981.25
In that call, Micron shared that it had strategic agreements, ranging from deals with automakers to hyperscalers, spanning three to five years. From those 16 agreements, it has $22 billion in deposits and financial commitments. In total, those agreements are expected to generate over $100 billion in revenue, a figure that may be conservative.
The news alone didn't push Micron back to its 52-week high of $1,255. But working to lock in future revenue over the years ahead can help it shed its cyclical reputation, building a stronger case for Micron as a long-term investment.
Jack Delaney has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Micron Technology. The Motley Fool recommends Nasdaq. The Motley Fool has a disclosure policy.
Akcie Strategy (MSTR) v první polovině roku 2026 klesly o 42,8 %, protože slábnoucí Bitcoin zničil prémii akcií a firma začala prodávat část svých bitcoinů na úhradu úroků. Dosud prodala 3 500 bitcoinů.
Shares of Strategy (MSTR +0.80%) -- formerly MicroStrategy -- have fallen by 42.8% in the first half of 2026, according to data from S&P Global Market Intelligence. The software provider that pivoted to becoming an aggressive Bitcoin treasury company has seen its strategy (no pun intended) begin to unravel with the price of Bitcoin down severely over the last twelve months.
To fund interest payments, Strategy has begun selling some of its Bitcoin, which has spooked the market. Here's why the stock was falling in 2026, and whether now could be a good time to buy the dip on this fallen giant.
Today's Change
(
0.80
%) $
0.75
Current Price
$
94.64
Following the price of Bitcoin When Bitcoin was over $100,000 a coin, Strategy actually achieved a market cap of over $100 billion, and had a nice premium to the underlying value of the assets on its balance sheet. Using this premium, Strategy was able to sell shares of its stock to buy more Bitcoin, thereby theoretically creating value per share due to the valuation premium.
With enthusiasm for cryptocurrencies beginning to wane and the price of Bitcoin falling, Strategy's stock premium has fully collapsed. Its share price is now down 80% from its highs, driven by this convergence with the underlying value of Bitcoin on its balance sheet, as well as the price of Bitcoin falling in the last year.
Now, with interest payments piling up on preferred stock and on outstanding debt used to buy Bitcoin, Strategy has been forced to liquidate some of its Bitcoin position to fulfill its ongoing obligations. As of this writing, it has been only 3,500 Bitcoin sold, which is a small amount relative to Strategy's balance sheet, but the signal to markets was nonetheless fear-inducing.
Image source: Getty Images.
Should you buy the dip? Strategy's old mandate was to keep buying Bitcoin through various forms of fundraising methods, be it debt, preferred stock, or issuing new shares. This party continued as the price of Bitcoin soared. Now, on the other side of the popping of a cryptocurrency bubble, a hangover of this business strategy is starting to rear its ugly head.
The stated value of its Bitcoin assets is over $50 billion at the current Bitcoin price of $64,000, but Strategy has $22.2 billion in liabilities, including a massive amount of preferred stock with double-digit annual interest payments, resulting in over $1 billion in funding requirements each year. With no underlying business to fund these interest payments, Strategy will be forced to sell even more Bitcoin, potentially leading to the dissolution of this entire business model unless the price of Bitcoin rises.
This makes the stock one investors should not buy the dip on right now.
The VanEck BDC Income ETF (NYSEARCA:BIZD) just delivered a jolt to income investors: its July distribution came in at $0.24 per share, roughly half the $0.48 paid in April. BIZD passes through the dividends of the business development companies it owns, so when the underlying BDCs strain, BIZD’s payout wobbles. With the fund down 14% over the past year and BDCs facing base-rate cuts and spread compression, the question is whether this distribution is a one-off dip or the start of something worse.
How BIZD Actually Pays You BIZD tracks the MVIS US Business Development Companies Index, holding a concentrated basket of publicly traded BDCs that lend to middle-market firms at floating rates over SOFR. When those loans pay interest, the BDCs distribute nearly all of it to shareholders to preserve their tax status, and BIZD passes that income through quarterly. Roughly 90% or more of BDC loan books are floating rate, which is why the Fed’s 75 basis point cut since September 2025, taking the target to 3.75%, hits BIZD’s income at the source.
The Four Holdings That Decide BIZD’s Fate Ares Capital (NASDAQ:ARCC | ARCC Price Prediction), the largest BDC by market cap at $13.48 billion, held its quarterly dividend at $0.48 for the eighth straight quarter. Q1 core EPS of $0.47 fell a penny short, but net investment income of $0.55 per share gives real cushion. Non-accruals ticked up to 2.1% from 1.8%, worth watching, but a $1.8 billion investment backlog and $6 billion in liquidity support the payout.
Blue Owl Capital (NYSE:OBDC) already made the cut official. On May 5, 2026, the board dropped the base dividend from $0.37 to $0.31, a 16% reduction in annualized payout. CEO Craig Packer cited “a more challenging earnings environment driven by lower base rates and tighter spreads.” Adjusted EPS of $0.31 now exactly matches the new dividend, meaning zero buffer. Shares are down 15% over the past year.
Blackstone Secured Lending (NYSE:BXSL) looks like the next domino. NII of $0.77 covered the $0.77 dividend at exactly 100%, down from 104% in Q4. New investments are being originated at 7.7% while assets rolling off yielded 9.1%, which mechanically compresses future income. Non-accruals jumped to 3.1% of fair value from 0.6% a quarter earlier. CEO Brad Marshall’s own words: “non-accruals increased during the quarter from historically low levels.” Another miss, and BXSL follows OBDC.
Main Street Capital (NYSE:MAIN) is the fund’s insurance policy. Distributable NII of $1.00 per share comfortably covers the $0.26 monthly regular plus a $0.30 quarterly supplemental, now paid for 19 consecutive quarters. NAV per share rose to about $33. MAIN’s lower-middle-market focus and equity co-investments generate returns other BDCs can’t match. Retail readers who like this profile may also want our 7 Monthly Dividend Stocks report.
Total Return Reality Check BIZD’s trailing 12-month distributions of $1.52 look generous against a roughly $13 share price, but the fund is down 6% year-to-date on top of last year’s decline. The forward annualized rate has reset to $0.96, so shoppers pricing this off the trailing yield are anchored to a payout that has already stepped down.
The Verdict BIZD’s distribution is at risk of further reduction. OBDC is done cutting for now, but BXSL is running on fumes at 100% coverage with rising non-accruals, and ARCC’s cushion is thinner than a year ago. MAIN is the anchor doing the heavy lifting. For investors who need a predictable check, MAIN offers more coverage than the blended pass-through. BIZD still makes sense for someone who wants diversified BDC exposure and can tolerate a variable payout that reflects whatever the underlying managers can actually earn each quarter.
Contact [email protected] for any questions or corrections.
Paramount zvažuje odchod z Kalifornie, pokud generální prokurátor Rob Bonta podá žalobu proti plánované fúzi s Warner Bros. Discovery za 110 miliard USD. Poradci doporučují přesun sídla a většinu z plánovaných výdajů ve výši 30 miliard USD mimo stát.
California’s escalating battle over Paramount’s proposed $110-billion merger with Warner Bros. Discovery could end with another corporate giant walking away from the Golden State.
Sources told Semafor advisers close to CEO David Ellison have encouraged him to consider moving the company’s HQ and redirecting much of its planned $30 billion spending outside the state if Attorney General Rob Bonta files a lawsuit to block the deal.
California’s escalating battle over Paramount’s proposed $110-billion merger with Warner Bros. Discovery could end with another corporate giant walking away from the Golden State. Getty Images
If Paramount ultimately relocates, it would join a growing list of major companies that have moved their headquarters after disputes with California regulators. Getty Images for CinemaCon Paramount has already committed to keeping both the Paramount and Warner Bros. studio lots operational if the merged company remains in California.
Executives have argued the merger would preserve and create jobs by backing roughly $30 billion in annual content spending at a time when film and television production have shifted to other states and Canada, resulting in thousands of entertainment jobs leaving California.
One adviser described California as an “inhospitable” place for Paramount to operate and said a lawsuit challenging the merger could ultimately push the company to leave the state.
Despite those discussions, Ellison is not sold on leaving California. He moved Paramount’s headquarters from New York to Los Angeles after acquiring the company last year and has spent most of his life in the state.
If Paramount ultimately relocates, it would join a growing list of major companies that have moved their headquarters after disputes with California regulators.
Paramount has already committed to keeping both the Paramount and Warner Bros. studio lots operational if the merged company remains in California. Getty Images
Last year, Paramount signed a lease for nearly 300,000 square feet of studio space in Bayonne, N.J. Getty Images Chevron shifted its headquarters from San Ramon, Calif. to Texas two years ago, while Oracle and Tesla have also established headquarters in the Lone Star State.
The company also has another potential foothold outside California: Last year, Paramount signed a lease for nearly 300,000 square feet of studio space in Bayonne, N.J.
“We continue to engage constructively with the remaining few regulators around the world still considering the merger, including State Attorneys General, and are prepared to address any legitimate antitrust issues,” Paramount said in a statement.
“We are confident this transaction raises no such concerns, as demonstrated by the dozens of antitrust authorities around the world that have carefully reviewed the transaction,” the statement continued.
Download The California Post App, follow us on social, and subscribe to our newsletters California Post News: Facebook, Instagram, TikTok, X, YouTube, WhatsApp, LinkedIn
California Post Sports Facebook, Instagram, TikTok, YouTube, X
California Post Opinion
California Post Newsletters: Sign up here!
California Post App: Download here!
Home delivery: Sign up here!
Page Six Hollywood: Sign up here!
Insilico Medicine a CMS oznámily další spolupráci na vývoji léku s využitím umělé inteligence pro onemocnění centrální nervové soustavy. Insilico může získat až zhruba 1,2 miliardy RMB na milníkových platbách plus licenční poplatky.
, /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a clinical-stage biotechnology company driven by generative artificial intelligence (AI), and China Medical System Holdings Limited ("CMS", 867.HK/8A8.SG), an open-platform innovative company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, today announced an additional AI‑empowered drug discovery collaboration targeting a mass-market indication in central nervous system with an innovative mechanism of action (MoA) identified by PandaOmics.
According to the collaboration agreement, the two parties will jointly advance the co-development of the R&D program by combining Insilico Medicine's validated AI platform and AI-enabled innovative drug discovery and development capabilities with CMS's experienced R&D team and deep therapeutic expertise. Insilico Medicine is eligible to receive up to approximately 1.2 billion RMB in milestone payments plus royalties. This partnership marks a deepening collaboration that leverages both parties' complementary strengths across the full value chain—from drug discovery and clinical development to commercialization.
Mr. Lam Kong, the Chairman, Chief Executive Officer, President and Executive Director of CMS said: "CMS is deeply impressed by Insilico Medicine's capability and productivity in AI drug discovery. We are happy to deepen our collaboration with Insilico Medicine. Insilico Medicine's leadership in AI drug discovery platforms and data-driven R&D is strategically complementary to CMS's capabilities in innovative R&D and clinical translation. In addition, CMS has built solid strengths in clinical development systems and efficiency, regulatory submission expertise, and commercialization network coverage. Our goal never changes: to accelerate the delivery of more clinically meaningful innovations to patients with greater speed and quality, better meeting the growing clinical needs."
"We are delighted to establish another collaboration with China Medical System just three months after our initial announcement," said Feng Ren, PhD, Co-CEO and Chief Scientific Officer of Insilico Medicine. "Our existing partnership, announced earlier this year, has been seamless and productive since its inception. In this new program, we value the input from the CMS commercialization team and are proud of the innovative Mechanism of Action (MoA) identified by PandaOmics, which streamlines the development of high-potential drugs, enhancing translational efficiency, and accelerating the transition of molecules from 'proof of concept' to life-changing patient therapies. We will continue to deepen our multi-dimensional collaboration in pipeline and clinical strategy and global partnerships to provide patients with more differentiated and accessible treatment options."
About CMS
CMS (HKEX stock code:867; SGX stock code: 8A8) is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.
CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.
CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the Cardiovascular-Kidney-Metabolic/gastroenterology/ophthalmology/ skin health businesses, bringing economies of scale in specialty fields.
About Insilico Medicine
Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend health longevity to people on the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK.
By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.com
Unum Group uzavřela další zajišťovací dohodu na dlouhodobou péči za 3,8 miliardy USD, čímž sníží expozici o 40 % oproti začátku loňského roku. Celkové rezervy na dlouhodobou péči klesnou z 14,8 miliardy USD na zhruba 11 miliard USD.
The “Duck Stock” Keeps Quietly Making Money for ShareholdersUnum Group NYSE: UNM said it has agreed to reinsure an additional portion of its long-term care insurance liabilities, marking the company’s third major external reinsurance transaction and its second involving long-term care.
On a conference call with analysts, President and CEO Rick McKenney said the agreement will cede $3.8 billion of long-term care statutory reserves, bringing total long-term care reserves reinsured to $7 billion. He said the transactions have reduced Unum’s exposure by 40% compared with the beginning of last year.
Get Unum Group alerts:
These 3 Insurance Stocks Made New 52-Week Highs: Still Time to Buy?The transaction is effective April 1, 2026, and is expected to close during 2026, subject to regulatory approvals and other customary closing conditions, according to Matt Royal, senior vice president of investor relations and treasury.
Deal Removes Remaining Individual LTC in Fairwind McKenney said the transaction removes all of Unum’s individual long-term care business that was originally written by Unum America and subsequently reinsured to Fairwind. The remaining liabilities in Fairwind will be group long-term care, which management said has a different risk profile.
3 Dividend Stocks Defying the Market Downturn Amid the Iran ConflictChief Financial Officer Steve Zabel said the company is reinsuring $3.8 billion of long-term care statutory reserves to Fortitude Re. Similar to Unum’s prior long-term care reinsurance deal, the biometric risk ceded to Fortitude Re will be retroceded to a highly rated global reinsurer, he said.
Zabel said the reinsured block represents 26% of Unum’s total long-term care block and 52% of its individual long-term care business. It includes about 50,000 policies with an average attained age of 76 years, compared with 86 years for the block reinsured in last year’s transaction.
The block is concentrated in active life reserves, which account for about 75% of reinsured reserves. Zabel said it also has a “materially richer benefit profile” than the business Unum will retain, with 83% of policies carrying inflation protection and 43% offering lifetime benefits.
Capital Cost and Pricing McKenney said the transaction will cost Unum $650 million of holding company excess capital, which he described as balanced against the risk reduction achieved. He also said Unum’s plan to return $1.3 billion to shareholders through dividends and share repurchases remains intact.
Zabel said management believes the most appropriate way to evaluate the transaction is relative to best estimate reserves, because that measure reflects the exposure being transferred. On that basis, he said the cost of the transaction is about 12% of best estimate reserves, compared with 10% for the 2025 transaction. The combined cost across both transactions is about 11%.
Zabel said the absolute cost relative to statutory reserves is higher because the 2026 block has a more adverse reserve profile. He said the block carries best estimate reserves nearly $700 million higher than statutory reserves, including a negative reserve margin of about $660 million.
Management said economic benefits from the deal include required capital release and tax benefits, which offset a significant portion of the gross cost. Zabel also said Unum is using temporary financing tied to future tax benefits that are expected to be realized over the next several years.
Remaining Long-Term Care Block Following the transaction, Unum’s total long-term care statutory reserves will decline from $14.8 billion to approximately $11 billion, according to Zabel. Group long-term care will represent about 70% of remaining long-term care reserves and 95% of insured lives.
Zabel said the shift toward group long-term care is “structurally important” because the group business carries less rich benefit designs, younger attained ages and lower ultimate risk than individual long-term care. He said the average daily benefit on group long-term care is about one-third of individual long-term care. He also said 77% of group long-term care policies have no inflation protection and only 7% have lifetime benefits.
Management said the transaction reduces sensitivities across key Fairwind assumptions, including premium rate increases, lapses and mortality, claim incidence, claim resolutions and interest rates. Zabel said those sensitivities decrease by 28% to 42%.
After the transaction, Fairwind will retain approximately $7.1 billion of group long-term care reserves, supported by about $2.1 billion of reserve margin and total protection of about $1.9 billion, Zabel said. Provident Life will continue to hold the remaining long-term care exposure, supported by diversification from a broader and growing product portfolio.
Capital Deployment Plans Unchanged Zabel said Unum expects year-end 2026 capital metrics to remain robust, including risk-based capital in the range of 400% to 425%, holding company liquidity of $1.5 billion to $2 billion and leverage of about 25%.
He said Unum’s 2026 capital sources and uses are unchanged, including expected capital generation of $1.4 billion to $1.6 billion and expected uses of about $1.5 billion, inclusive of roughly $1.3 billion of share repurchases and dividends.
“There is no change to our priorities, no change to our planned actions, and no change to our expected return of capital to shareholders this year as a result of the transaction,” Zabel said.
Analysts Ask About Future LTC Actions During the question-and-answer session, analysts asked whether Unum could pursue additional long-term care reinsurance transactions, including for group long-term care. McKenney said the company continues to talk to counterparties about different parts of the block but emphasized that future deals would depend on market conditions and shareholder value.
“We would like to remove that risk from our balance sheet overall,” McKenney said of long-term care. “At the same time, we’ve also been very clear to say we’ll only do so if it makes sense from a shareholder perspective.”
McKenney said Unum remains focused on its core employee benefits franchises in the U.S., U.K. and Poland while continuing to manage the closed long-term care block. He described the new agreement as “another meaningful step” in the company’s closed block strategy.
About Unum Group NYSE: UNMUnum Group NYSE: UNM is a leading provider of employee benefits in the United States and selected international markets, specializing in disability, life, accident and critical illness insurance. Through both fully insured and self-funded arrangements, the company offers group coverage designed to protect income and mitigate financial hardship for employees and their families. Its portfolio includes short-term and long-term disability plans, group life and accidental death & dismemberment (AD&D) policies, as well as critical illness and hospital indemnity products.
In addition to its core product lines, Unum Group markets voluntary benefits under its Colonial Life brand, allowing employees to purchase supplemental insurance such as accident, cancer, and dental coverage directly through payroll deductions.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Unum Group Right Now?Before you consider Unum Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Unum Group wasn't on the list.
While Unum Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.
Insider Astera Labs Manuel Alba prodal 8 491 akcií za 3,9 milionu USD v rámci předem stanoveného plánu 10b5-1. Hlavní zprávou je ale růst tržeb o 93 % na rekordních 308,4 milionu USD.
Manuel Alba, a Director at Astera Labs, Inc. (ALAB 1.07%), executed a sale of 8,491 shares of common stock on July 1, 2026, according to an SEC Form 4 filing.
Transaction summaryMetricValueTransaction value$3.9 millionShares sold (indirectly held)8,491Post-transaction shares (directly held)2,351Post-transaction shares (indirectly held)291,863Transaction value based on SEC Form 4 weighted average sale price ($458.38); post-transaction value based on July 1, 2026 market close ($430.86).
Key questionsWhat was the mechanism for this transaction?
The sale was executed automatically under a Rule 10b5-1 trading plan that Manuel Alba adopted on May 29, 2025, which allows insiders to schedule trades in advance to avoid concerns regarding material non-public information.How are the remaining shares held?
The vast majority of the reported equity is held indirectly, with 286,863 shares owned by Casa Alameda 2007, LLC, where the Director serves as manager, and 5,000 shares held by a spouse.What is the recent performance context for the company?
As of July 2, 2026, shares were priced at $406.42, following a period of appreciation where the stock delivered a 386% total return in the year leading up to the transaction date.What is the company's current financial profile?
Headquartered in Santa Clara, the company operates in the semiconductor industry with a market capitalization of $70 billion and reported trailing twelve-month revenue of $1.0 billion as of July 7, 2026.Company OverviewMetricValueShare Price (as of market close 2026-07-02)$406.42Market Capitalization$69.7 billionRevenue (TTM)$1.0 billionNet Income (TTM)$267.6 millionCompany SnapshotAstera Labs develops and markets semiconductor-based connectivity solutions through its Intelligent Connectivity Platform, which comprises data, network, and memory connectivity products designed to serve cloud computing and artificial intelligence infrastructure markets.The company generates revenue through a software-defined architecture approach that enables customers to deploy and operate high-performance cloud and AI systems at scale, leveraging proprietary semiconductor technology and integrated software solutions.The company primarily serves hyperscale cloud service providers and enterprise customers requiring advanced connectivity infrastructure for AI and cloud computing applications.Astera Labs is a semiconductor connectivity specialist founded in 2017 that has achieved significant scale with $1.0 billion in TTM revenue and a market capitalization of $69.7 billion. The company's Intelligent Connectivity Platform addresses critical infrastructure bottlenecks in cloud and AI deployments, positioning it at the intersection of two of the highest-growth technology markets. With a lean operational footprint of 440 employees and TTM net income of $267.6 million, Astera Labs demonstrates strong operational leverage and profitability in a capital-intensive industry.
What this transaction means for investorsThis sale ultimately seems like a director trimming a rounding error off a very large win, and the proportions make that clear. Alba let go of 8,491 shares under a plan he set more than a year ago, but he still controls roughly 292,000 shares, almost all of it held through an LLC he manages. Given that the director parted with under 3% of his position on a preset schedule, selling at $458 after this kind of run is nothing to read too deeply into.
That’s also partly because the business is firing on every cylinder. Astera's first-quarter revenue hit a record $308.4 million, up 93% from a year earlier, with PCIe 6 products now more than a third of the mix and non-GAAP operating margin near 36%. CEO Jitendra Mohan tied the growth to demand for the company's connectivity platform and its new Scorpio switches ramping into the second half. Of course, it’s important to watch valuation after this kind of run-up. At a $70 billion market cap after a year in which shares have basically quadrupled, this stock is priced for years of what investors might expect to be flawless execution, so any dwindling expectations could lead to a strong reset in the stock’s price.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool recommends Astera Labs. The Motley Fool has a disclosure policy.
Teva uvedla, že její anti-IL-15 protilátka přinesla ve 24týdenní studii fáze 1b u vitiliga povzbudivé výsledky. Firma plánuje letos zahájit studii fáze 2.
MarketBeat Week in Review – 02/03 - 02/07Teva Pharmaceutical Industries NYSE: TEVA said its internally developed anti-IL-15 antibody produced encouraging 24-week efficacy results in a phase 1b proof-of-concept study for vitiligo, as the company highlighted the program as part of its broader shift toward a biopharma-focused growth strategy.
During a conference call, President and CEO Richard Francis called the data “a milestone” in Teva’s “Pivot to Growth” plan and said 2026 is expected to include eight key events for the company, up from a prior expectation of seven following the addition of an ecopipam NDA filing.
Get TEVA alerts:
Teva Pharma: Why This Generic Drug Giant Is a Smart Buy NowFrancis said Teva’s pipeline includes several programs that the company believes could each become $1 billion products in their respective indications, including anti-IL-15, duvakitug, emricasan, DARI, ecopipam and olanzapine-related programs. He said Teva expects its innovative portfolio to generate $3.5 billion of revenue in 2026.
Vitiligo Study Shows Facial and Total Body Responses Eric A. Hughes, Teva’s EVP of Global R&D and Chief Medical Officer, said vitiligo is an autoimmune disease in which an immune reaction destroys melanocytes, leading to loss of pigmentation. He said the disease affects about 0.5% to 2% of the global population and carries a psychological burden, including anxiety, depression and social isolation.
2 Generic Drug Stocks Ready to Surge in 2025Hughes said the only FDA-approved treatment currently available is a topical therapy for patients with less than 10% body surface area involvement, leaving a need for systemic options that can treat the whole body.
The phase 1b study evaluated Teva’s anti-IL-15 antibody in approximately 38 patients. Participants received one subcutaneous dose at day zero and another at week 12, with efficacy measured at 24 weeks. Hughes said 66% of patients in the study had skin involvement greater than 10% of their body surface area.
Teva reported the following 24-week results after two doses:
42% of patients achieved F-VASI50, representing at least a 50% improvement in facial vitiligo. 21% of patients achieved F-VASI75, representing at least a 75% improvement in facial vitiligo. 7% of patients achieved T-VASI50, representing at least a 50% improvement in total body vitiligo. 75% of patients reported improvement in facial skin using the facial Patient Global Impression of Change score, with half of those reporting “much” to “very much” improvement. 55% of patients reported improvement in total skin using the total Patient Global Impression of Change score. Hughes said the patient-reported outcomes were particularly meaningful because patients monitor their skin daily and may be strongly affected by changes in appearance.
Company Highlights Quarterly Dosing Potential Hughes said Teva believes its anti-IL-15 antibody is differentiated by its potency, long half-life and target engagement. He described the molecule as “Teva-born” and said it was created by the same internal team that developed duvakitug.
According to Hughes, the antibody has a half-life of about 38 days. He said the company observed rapid suppression of free IL-15 levels in serum within one or two days, and at the top dose, suppression below the limit of quantitation extended to about 80 to 90 days. Based on those data, Hughes said dosing once per quarter is a “strong possibility.”
Hughes said the drug has been “very well tolerated” to date, with no safety signals seen so far. In response to an analyst question, he said Teva has followed patients from earlier studies for extended periods, including out to about 400 days in some phase 1 work, and has not seen adverse events associated with IL-15 rebound as levels return to baseline.
Teva Compares Data With Oral JAK Programs Hughes compared the phase 1b results with published data from upadacitinib, an oral JAK therapy that he said recently received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use.
He said Teva’s F-VASI50 result of 42% compared with 38% and 39% in the upadacitinib data he referenced. Teva’s F-VASI75 result of 21% compared with 19% and 14%, while its T-VASI50 result of 7% compared with 6% and 11%.
Hughes said Teva views the comparison as encouraging, particularly because its product is being developed as a subcutaneous injection given once every quarter. He contrasted that with daily oral JAK therapy, which he said carries a black box warning.
Phase 2 Plans and Additional Indications Teva said it has already met with the FDA and is incorporating the agency’s feedback into a phase 2 study expected to begin this year. Hughes said the company plans dose-ranging work in phase 2b and is discussing a seamless study design that could allow the program to move efficiently toward phase 3.
Hughes said Teva expects facial VASI and total VASI endpoints to be used in later-stage development, with baseline criteria likely to include greater than 0.5 on facial VASI and greater than five on total VASI. He also said Teva will continue monitoring phase 1b subjects out to 80 weeks.
Teva also emphasized potential applications for anti-IL-15 beyond vitiligo. Hughes said IL-15 may be relevant in alopecia areata, celiac disease, eosinophilic esophagitis and atopic dermatitis. The company expects proof-of-concept data from a phase 2a celiac disease study in the second half of the year.
That celiac study, Hughes said, includes about 50 patients in a placebo-controlled gluten challenge design. Patients receive either active treatment or placebo, then undergo a gluten diet challenge, with biopsies used to evaluate effects on gut histology. Hughes said the crypt depth-to-villus height ratio will be the most important readout.
Francis closed the call by saying the anti-IL-15 vitiligo data represent the second of eight expected milestones for Teva this year, with additional pipeline updates anticipated in the coming months.
About Teva Pharmaceutical Industries NYSE: TEVATeva Pharmaceutical Industries Ltd. NYSE: TEVA is an Israeli multinational pharmaceutical company and one of the world's largest manufacturers of generic medicines. The company's core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.
Teva's product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Teva Pharmaceutical Industries Right Now?Before you consider Teva Pharmaceutical Industries, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.
While Teva Pharmaceutical Industries currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Amazon vydá dluhopisy za 25 miliard USD na financování rozšíření datových center. Firma chce letos investovat kolem 200 miliard USD do kapitálových výdajů.
Amazon (AMZN 0.69%) is reported to have made a shocking decision in recent days. According to CNBC, it is issuing $25 billion in debt to fund its data center build-out. While it doesn't plan to issue any more debt beyond that in 2026, it's a big deal because Amazon's long-term debt has been soaring in the past few years.
Building data centers isn't cheap, and the cash has to come from somewhere, but is this the right move, or should it scare investors?
Image source: Getty Images.
The payoff could be immense In recent years, Amazon's debt load has skyrocketed from the company's historical levels.
AMZN Total Long Term Debt (Quarterly), data by YCharts.
The latest $25 billion sale of debt adds to this total, but Amazon has the cash flow to fund the repayment. The reality is that it's vital for the company to grab as much cloud infrastructure market share as possible in these early days of the AI build-out; it will be more difficult to win clients away from other cloud providers once everyone has their preferred vendor.
The company is currently leading the way among AI hyperscalers in data center construction plans, and it expects to lay out around $200 billion in capital expenditures this year. Over the past 12 months, Amazon generated just shy of $150 billion in cash from operations, so the gap between funds coming in and cash flowing out had to be closed somehow.
AMZN Cash from Operations (TTM), data by YCharts; TTM = trailing 12 months.
As a result, investors should not feel too blindsided by this debt issuance. But is it worth it?
CEO Andy Jassy said in his shareholder letter that the nature of a cloud computing business requires increased capital input when it's growing rapidly. Data centers aren't cheap to bring online, but they do have great payoffs over long time frames. Jassy also mentioned that a significant amount of the new computing capacity that $200 billion will buy is already under contract to customers, so it isn't just taking a leap of faith when building these data centers.
Once the construction is over and the company is benefiting from a much larger cloud computing footprint, its gains in revenue and cash flow will be immense, and should dwarf any concerns about its rising debt load. Current market conditions and demands dictate that management build more data centers, and that's exactly what it's doing.
With Amazon Web Services being a major part of the cloud computing landscape and an important part of the company's overall business, now is a perfect time to buy the stock, as Amazon's growth over the next few years could be immense.
FuelCell Energy oznámila spolupráci se Siemens na rychlém nasazení komerčních projektů s roztavenými karbonátovými palivovými články. Firma má backlog ve výši 1,14 miliardy USD a pipeline vzrostla mezi 1. a 2. čtvrtletím 2026 o 267 % sekvenčně.
Patient FuelCell Energy (FCEL 8.56%) investors have been rewarded thus far this year, with the power plant fuel cell specialist's stock rising more than 187% in 2026 and over 275% in the past 12 months.
Shareholders received more good news this week as FuelCell announced a collaboration and memorandum of understanding with Siemens (SIEGY 0.15%). Through this partnership, Siemens will support the rapid deployment of commercial projects involving molten carbonate fuel cells designed and produced by FuelCell Energy.
Image source: Getty Images.
This is a strong signal as to where FuelCell is heading. Siemens' electrical infrastructure expertise, sheer size, and capabilities will enable the company to scale at a new level.
FuelCell has a large backlog of projects totaling $1.14 billion as of the company's second-quarter 2026 earnings report. The sales pipeline grew 267% sequentially between Q1 and Q2 of 2026, signaling that the company has growing demand.
Today's Change
(
-8.56
%) $
-1.97
Current Price
$
21.03
FuelCell remains a higher-risk investment, with a beta of 2.3; investors in the company need a stomach for volatility. Yet, as shares trade well below their 52-week high of $37.88, FuelCell looks like a rocket ship poised to launch into the AI power crisis.
Investors are also concerned about dilution, as FuelCell recently announced an offering of new common stock worth about $225 million. The short-term pain seems relatively insignificant given the opportunity FuelCell has in the intermediate and long terms. Data center power demand is expected to double in the next year.
On-site generation is the future for data centers that desperately need reliable power. Successful execution and scaling of FuelCell's technology could lead to serious recurring revenue for years to come.
If you are OK with short-term share price volatility, you might want to give this infrastructure stock a closer look.
Catie Hogan has positions in FuelCell Energy. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
MasTec uzavřel dohodu o koupi společnosti The Superior Group za zhruba 1,65 miliardy USD, aby posílil infrastrukturu pro AI a datová centra. Firma očekává uzavření ještě tento měsíc a transakce má být okamžitě přínosná pro výnosy, EBITDA i EPS.
3 Stocks Cashing In on AI While Everyone Watches NVIDIAMasTec NYSE: MTZ said it has entered into a definitive agreement to acquire The Superior Group, an electrical infrastructure contractor focused on data centers and other mission-critical markets, in a transaction valued at approximately $1.65 billion upfront.
Chief Executive Officer Jose Mas said on the conference call that the acquisition expands MasTec’s position in infrastructure tied to artificial intelligence, cloud computing and digital infrastructure. He described Superior as “one of the premier electrical infrastructure contractors” serving hyperscalers, data center developers and mission-critical customers across the United States.
Get MasTec alerts:
3 Energy Stocks to Buy as AI Power Demand Surges—and 2 to Avoid“We believe this represents a generational infrastructure investment opportunity for the companies with the capabilities, skilled workforce, and track record to help build it,” Mas said.
Deal Terms and Financing Chief Financial Officer Paul DiMarco said the purchase price consists of $1.175 billion in cash and $475 million in MasTec common stock, along with a performance-based earn-out tied to Superior’s financial results over the three years after closing. MasTec expects to issue approximately 1.2 million shares as part of the equity consideration.
This infrastructure construction stock: Is it ready to pop?DiMarco said MasTec expects to fund the cash portion through cash on hand, borrowings under its existing credit facility and delayed-draw term loan facilities arranged for the transaction. The company expects the deal to close later this month after regulatory clearance.
The upfront consideration represents 6.9 times Superior’s expected 2026 EBITDA, DiMarco said. In response to an analyst question, Mas said MasTec expects the earn-out to add about one additional turn to the upfront multiple, depending on Superior’s performance. He added that the earn-out is uncapped and based on performance targets over three years.
Expected Financial Contribution MasTec said it expects the acquisition to be immediately accretive to revenue, adjusted EBITDA, earnings per share and cash flow from operations.
For 2026, MasTec expects Superior to contribute approximately five months of earnings to consolidated results, including:
$800 million to $900 million of revenue; $100 million to $150 million of adjusted EBITDA; and $0.50 to $0.65 of adjusted earnings per share. For the full year 2026, Superior is projected to generate approximately $1.6 billion to $1.7 billion of revenue and $225 million to $250 million of adjusted EBITDA. Looking ahead to 2027, MasTec expects Superior to generate $2.2 billion to $2.5 billion of revenue and $250 million to $275 million of adjusted EBITDA.
DiMarco said the expectations are preliminary, reflect a conservative approach and do not include revenue synergies, cross-selling opportunities or operational benefits from combining the businesses. Superior will become a new operating group within MasTec, and its results are expected to be reflected in the Power Delivery segment.
Data Center and Power Infrastructure Focus Mas said the transaction strengthens MasTec’s position in markets where power infrastructure, communications infrastructure and data center development are converging. He said MasTec already delivers critical infrastructure that brings power, communications and energy to data center campuses, while Superior adds capabilities “inside the campus” through electrical construction, integrated systems, prefabrication, commissioning support and maintenance services.
Mas said the combination gives MasTec a broader offering across the infrastructure value chain. He said customers increasingly want larger, integrated partners that can self-perform work, mobilize labor at scale and deliver complex projects with speed and reliability.
In response to a question from Citigroup analyst Andy Kaplowitz, Mas said MasTec has historically performed much of the work outside the building, while Superior performs work inside the building. He said the combination could allow MasTec to offer a more turnkey service to customers, including general contractors.
Superior’s Workforce and Growth Profile Superior has approximately 3,000 employees. Mas said access to skilled labor is one of the most important competitive advantages in the industry and described Superior’s workforce as one of the company’s most attractive assets.
During the Q&A, Mas said Superior is currently an all-union business and characterized the transaction as “a bet on labor scarcity.” He said Superior’s workforce has grown almost 400% over the last few years and that the company has shown a strong ability to recruit, train and deploy skilled electrical labor.
Mas also said Superior has grown 100% organically, with no history of acquisitions contributing to its recent expansion. He said the business has operated primarily in three states in recent years, but has signed contracts that will expand it into five states next year, with the potential for additional state expansion after that.
Asked about Superior’s backlog, Mas said MasTec conducted project-by-project due diligence and has “enormous conviction” in its 2027 expectations. He said Superior has five large customers and a blue-chip customer base, adding that MasTec expects backlog to grow significantly through the balance of the year.
Balance Sheet Outlook DiMarco said MasTec expects pro forma net leverage to be modestly above two times at closing, but expects net leverage to decline below two times by the end of 2026 due to the combined company’s expected earnings and cash flow generation.
He said the transaction should generate a low double-digit return on invested capital in the first year and support MasTec’s stated target of 16% in 2028. DiMarco also said MasTec remains committed to maintaining strong liquidity and preserving its investment-grade credit profile.
Mas said the company sees the data center build-out as still being in its early stages, based on conversations with customers, hyperscalers and advisors during due diligence. He acknowledged that the market may see “ups and downs,” but said MasTec remains bullish on the long-term opportunity.
About MasTec NYSE: MTZMasTec, Inc is a diversified infrastructure construction company that provides engineering, fabrication, installation and maintenance services across a broad range of end markets. Its principal activities encompass the development of communications networks, oil and gas pipeline systems, electrical transmission and distribution facilities, industrial installations and renewable energy projects.
The company traces its roots to a small cable installation operation in Miami and has grown through a series of strategic acquisitions to become one of the largest infrastructure contractors in North America.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in MasTec Right Now?Before you consider MasTec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MasTec wasn't on the list.
While MasTec currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Stacks navrhuje PoX-5, který by držitelům bitcoinu umožnil výnos bez přesunu BTC z hlavní sítě. 15 % přebytečných příjmů má jít do rezervního fondu protokolu.
Stacks, the Bitcoin Layer 2 network, is proposing a significant upgrade to its consensus mechanism that would let Bitcoin holders earn yield on their BTC without ever moving it off the main chain. The kicker: 15% of all excess revenue gets funneled into a reserve fund designed to keep the whole system solvent even during lean times.
The upgrade, dubbed PoX-5 (Proof-of-Transfer version 5), introduces a waterfall distribution model. Protocol bond holders sit at the top of the payment queue, with an initial target yield of roughly 3% APY. These bonds require a six-month lockup period. Only after those obligations are met does the remaining revenue flow downhill.
Whatever is left after paying bond holders, the excess miner revenue, gets split two ways. STX-only stakers receive 85% of the surplus. The protocol reserve fund absorbs the remaining 15%.
Advertisement
To participate, Bitcoin holders lock their BTC on the Bitcoin Layer 1 network using a timelock mechanism and pair it with STX, the native token of the Stacks network. No bridging required. No custodial transfers.
Building a 1.2-year safety buffer The 15% reserve allocation isn’t arbitrary. Simulations run across 210 two-week cycles, roughly eight years of modeled data, project that the reserve fund would accumulate enough to cover 1.2 years of yield commitments.
The system also includes capacity constraints and real-time coverage ratio monitoring. There’s no slashing mechanism for participants, meaning stakers don’t risk losing their principal if something goes sideways with the network.
The whitepaper laying all of this out was published on May 13, 2026. Since then, the Stacks community has been reviewing the associated SIP (Stacks Improvement Proposal) documents related to the bootstrap phase. No formal votes or launches have been finalized yet.
Stacks’ track record with Proof-of-Transfer The original PoX mechanism has been operational since January 2021, and over that period, the protocol has distributed more than 4,200 BTC to participants under prior consensus versions. PoX-5 is an evolution of that infrastructure, adding structured yield products and reserve mechanics on top of existing plumbing.
The upgrade also serves a dual purpose beyond yield generation. By requiring participants to pair BTC with STX, it creates organic demand for the Stacks native token. More staking activity means more STX gets locked up, which theoretically supports the token’s value while simultaneously enhancing network security through increased participation.
Disclosure: This article was edited by Editorial Team. For more information on how we create and review content, see our Editorial Policy.
StanChart varuje, že nejasná komunikace společnosti Strategy ohledně využití BTC na podporu STRC může Bitcoin krátkodobě tlumit. Firma už prodala BTC za 216 milionů USD a drží 843 775 BTC.
Strategy founder and chairman Michael Saylor again took to social media on Sunday to offer his latest signal to investors as one analyst sees Saylor’s messaging as needing more clarity to help Bitcoin regain its momentum.
“Orange dots tell only part of the story,” was Saylor’s message on Sunday in a post that accompanied a chart from Saylortracker.com, similar to previous social media messages that have preceded news of Strategy's Bitcoin (BTC) purchases, typically announced the day after his posts.
In recent weeks, the largest digital asset treasury company and a major BTC holder, has moved away from its long-time “never sell Bitcoin” approach to a willingness to sell the biggest crypto as needed to fund dividends for holders of its STRC preferred stock and to replenish its cash reserves. Earlier this month, Strategy sold $216 million worth of Bitcoin, reducing its total holdings to 843,775 tokens, according to a July 6 filing with the US Securities and Exchange Commission.
“Orange dots tell only part of the story.” Source: Michael Saylor
Days earlier, Strategy unveiled a capital framework allowing Bitcoin sales to fund dividends, increased the annual dividend rate on its STRC preferred stock to 12%, and disclosed that its US dollar reserve had grown to $2.55 billion.
Standard Charter’s global head of digital assets research, Geoff Kendrick, believes recent Strategy’s actions — and Saylor's manner of communicating them — “are muddying the waters for BTC near-term.”
“We think effective communication of MSTR’s new strategy (using BTC to back STRC) is key to reassuring markets that wholesale selling is unlikely; this should in turn support BTC prices,” Kendrick wrote in a note to clients on Friday. “Indeed, if this signalling proves effective, it should remove the need for MSTR to actually sell any BTC by supporting STRC’s price,” he said.
StanChart sees inconsistencies in “never sell” approachKendrick said that Strategy’s long-held “never sell” approach limited what the company could with its industry-biggest digital asset treasury.
“The problem with the ‘never sell’ approach is that it limits what MSTR’s BTC holdings can do — or, perhaps more importantly, what they are perceived to be doing,” the StanChart analyst said. “MSTR has started to shift its communication strategy on this in recent months. It has sold BTC twice and recently announced a BTC monetization program.”
Source: Standard Chartered Bank
Still, he sees Strategy’s “market signaling” will improve soon. He expects that to bring clarity to the outlook for Bitcoin, on which StanChart maintains its $100,000 year-end forecast.
Shares struggle from year low ahead of earnings reportInvestors who bought into the Strategy narrative have not had an easy time in the past 12 months. The STRC preferred shares were formulated to hold a price of $100 apiece. Shareholders saw that par value fall to the wayside last month, to the lowest value since the preferred stock was introduced a year ago.
The common shares, trading under the MSTR ticker, have lost more than 70% of their value since July 2025, closing at $94.64 per share on Friday, down from a 52-week high of $457.22.
The company is slated to report second-quarter earnings on July 30, with analysts consensus of $4.28 per share, according to Yahoo Finance data. Earnings have fallen short of analyst forecasts in six of the last eight quarters, according to Fintel.io data, including a 33.76% negative surprise in the first quarter of 2026.
Magazine: Will the crypto lobby's $189M campaign get CLARITY over the line?
Cointelegraph is committed to independent, transparent journalism. This news article is produced in accordance with Cointelegraph’s Editorial Policy and aims to provide accurate and timely information. Readers are encouraged to verify information independently.
Spotové XRP ETF zaznamenaly za uplynulý týden první červený týden po více než dvou měsících, když z fondů odešlo 7,29 milionu USD. XRP za týden kleslo o 3,2 %.
The XRP products continue to operate differently than those tracking BTC and ETH.
For weeks and weeks, the spot Ripple ETFs, alongside HYPE and sometimes SOL, dominated all cryptocurrency-related exchange-traded funds, while the market leaders suffered.
However, this trend has finally changed as the financial vehicles tracking the performance of the cross-border token turned red in the past week for the first time in over two months.
Streak Broken Although the actual numbers were not as impressive as they were back in October, November, and December last year when the XRP ETFs launched, they were still in the green for nine consecutive weeks. Moreover, the only week that broke that streak saw a minor $35.21K (not millions) in net outflows, so it doesn’t really count. Within this timeframe, the total net inflows rose from under $1.29 billion to a new all-time high of $1.49 billion as of July 2.
However, the tides finally turned in the past five business days. Interestingly, though, only one day was in the red, with $7.29 million leaving the funds on July 8. A minor $107.38K entered the funds on Friday, while the other three trading days saw no reportable action, according to SoSoValue data.
Spot XRP ETF Inflows. Source: SoSoValue This is rather concerning as XRP has seen similar net inflow-free days in the past, but that wasn’t the case in the last few months. Now, though, investors appear to have turned their attention away from Ripple’s token and back to the market leaders. As reported yesterday, both the Bitcoin and Ethereum ETFs recorded their first green week in two months, with net inflows of almost $200 million and $84 million, respectively.
XRP Price Stalls Despite the major net inflows for nine weeks, Ripple’s native coin failed to capitalize and record any substantial gains in that time. However, the net ouflows in the past week seem to have harmed it, as current data from CoinGecko shows a 3.2% decline over the past week.
XRP challenged the $1.15 resistance earlier this week, but it was halted there, and the subsequent rejection pushed it south to under $1.10. Although it has rebounded to that level now, the uncertainty continues as many analysts expect a major move ahead.
You may also like: XRP Stalls at $1.10: Could Quiet On-Chain Activity Be the Calm Before a Bigger Move? XRP’s On-Chain Data Flashes Warning While Sellers Continue to Dominate Japanese Firms Are Boosting BTC and XRP Holdings – SBI VC Trade Reveals Why The direction, as usual, is unknown, but the overall belief within the crypto community is that XRP has reached a decision point and it could either head below $1.00 soon or rocket toward new local peaks.
Chief Medical Officer UroGen Pharma Mark Schoenberg prodal 10 000 akcií za $400,000 v rámci předem daného plánu 10b5-1. Po transakci dál drží 119 763 akcií.
Mark Schoenberg, Chief Medical Officer, sold 10,000 ordinary shares of UroGen Pharma Ltd. (URGN 4.15%) on July 9, 2026, for a total value of $400,000, according to an SEC Form 4 filing.
Transaction summaryMetricValueTransaction value$400,000Shares sold10,000Post-transaction shares (directly held)119,763Post-transaction value$4.82 millionKey questionsWhat was the mechanism for this transaction?
The sale was conducted under a pre-established Rule 10b5-1 trading plan adopted on August 15, 2025, which provides for automated execution and represents the concluding transaction of that plan's schedule.What is the scale of the insider's remaining direct investment?
Mark Schoenberg continues to hold 119,763 ordinary shares directly.What financial context does UroGen Pharma Ltd. present at this valuation?
The biotechnology company, which develops solutions for urothelial and specialty cancers, reported trailing 12-month revenue of $140.5 million and a net loss of $133.2 million.How does the current market capitalization compare to the transaction level?
The disposition occurred with the company's market capitalization at $2.0 billion, following a period of performance where shares were priced at $40.23 as of the July 9, 2026 market close.Company OverviewMetricValueShare Price (as of market close 2026-07-09)$40.23Market Capitalization$2.0 billionRevenue (TTM)$140.5 millionNet Income (TTM)-$133.2 millionCompany SnapshotUroGen Pharma develops and commercializes innovative solutions for urothelial and specialty cancers, with primary revenue sources including Zusduri, a sustained-release mitomycin formulation for non-muscle invasive bladder cancer, and RTGel, a proprietary reverse thermal gelation hydrogel technology platform.The company operates a commercial-stage biotechnology business model focused on bringing novel therapeutic formulations to market, generating revenue through product sales while continuing to invest in research and development for pipeline expansion.UroGen's primary customers are urology and oncology specialists, with target markets encompassing patients with non-muscle invasive bladder cancer and other urothelial malignancies requiring adjuvant chemotherapy and specialized treatment modalities.UroGen Pharma is a commercial-stage biotechnology company with a $2 billion market capitalization, demonstrating significant growth momentum with a one-year stock appreciation of 191.31%. The company has achieved meaningful revenue scale at $140.5 million TTM while maintaining a focused pipeline strategy centered on proprietary drug delivery technologies for underserved oncology indications. UroGen's competitive advantage derives from its proprietary RTGel platform technology and its established commercial infrastructure for specialty cancer therapeutics, positioning the company as a differentiated player in the niche urothelial cancer treatment market.
What this transaction means for investorsFirst, it’s important to note that this was the final trade in a 10b5-1 plan Schoenberg set almost a year ago, so the timing was locked in long before Schoenberg could know how the firm was necessarily going to be performing. He still holds nearly 120,000 shares worth close to $4.8 million, and a chief medical officer keeping a stake that size while the company's newest drug is inflecting isn't sending any signal about the science.
The launch of Zusduri, UroGen’s new bladder cancer therapy, is what matters here, and it's going well. UroGen's first quarter revenue jumped 152% to $51 million, as a result of the launch, which brought in $29.2 million and more than doubled quarter over quarter after a permanent insurance billing code kicked in. CEO Liz Barrett called January's J-code "a major inflection point," and unique prescribers jumped to 256 from 102 in a single quarter. More recently, the firm announced that the FDA cleared its investigational new drug application for UGN-501, enabling a planned Phase 1 study in patients with non-muscle invasive bladder cancer. It’s expected to begin in the fourth quarter.
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Thajsko chce v rámci nové razie prověřovat transakce v USDT společně s regulátory cenných papírů. Zároveň zvažuje, že u hotovostních vkladů od 5 milionů bahtů bude nutné doložit původ peněz.
Thailand’s central bank is considering measures requiring anyone depositing 5 million baht ($150,000) or more in cash to prove the origin of the funds.
This is part of a fourth-quarter push that also puts Tether (USDT) transactions under a joint audit with securities regulators.
Why Thailand Is Watching USDTBank of Thailand (BOT) Governor Vitai Ratanakorn framed the measures as a strike against the country’s grey economy. The push, reported by Thansettakij, extends the central bank’s grey-money campaign to digital assets.
Vitai said in January that roughly 40% of USDT sellers on local platforms were foreigners. He argued they should not be operating in Thailand.
The BOT is now working with the Securities and Exchange Commission (SEC) to review unusually high-volume USDT trading. Authorities have identified transactions that may indicate disclosure avoidance or the movement of funds outside standard financial channels.
Follow us on X to get the latest news as it happens
Cash and Bullion Rules TightenThe deposit rule complements checks already applied to large withdrawals. Since April, cash withdrawals above 5 million baht have faced enhanced due diligence. The value of large cash withdrawals has since fallen 35%.
The BOT is reviewing the legal framework before issuing the deposit requirements.
“In addition, it is considering measures for high-value banknote exchanges — such as bringing in large quantities of 1,000-baht notes to exchange for 100- or 500-baht notes — which may require an explanation of the reason for the transaction,” the report read.
In addition, the BOT has tightened oversight of gold trading to limit its impact on the baht and detect suspicious activity.
“The measures we are implementing are not short-term fixes; they require the continuous deployment of multiple parallel strategies,” Governor Vitai said.
The coming quarter will test how far the BOT can extend its reach.
Subscribe to our YouTube channel to watch leaders and journalists provide expert insights
Meta za deset let zhodnotila investici 10 000 USD na 58 000 USD včetně dividend. Akcie v pátek přidaly asi 6 % díky obnovenému zájmu o AI strategii Marka Zuckerberga.
Meta Platforms (META +6.16%) just closed out quite an eventful week. Shares of the social media giant jumped about 6% on Friday alone as investors warm back up to CEO Mark Zuckerberg's aggressive artificial intelligence (AI) strategy.
The company has given them plenty to work with this year. Growth is accelerating, its new AI lab released its first model this spring, and capital spending guidance now tops $125 billion.
But let's zoom out for a second. How has the stock done over the long haul? Specifically, how much would $10,000 invested in Meta a decade ago be worth today?
Image source: Getty Images.
How the math works out In 2016, Meta -- then still called Facebook -- traded at an average price of about $116 per share. A $10,000 investment at that price would have bought about 86 shares. With the stock trading near $670 as of this writing, those shares would be worth roughly $57,600 today, a nearly sixfold gain.
And dividends sweeten the total a little. Meta initiated its first-ever dividend in early 2024 at $0.50 per share quarterly, and the quarterly payout now stands at $0.525 per share. Those 86 shares would have collected a bit over $400 in dividends so far, bringing the total value to about $58,000.
That works out to a compound annual growth rate of about 19%.
The engine hasn't slowed Of course, none of that return is available to anyone buying today. What matters now is whether the business that produced it is still performing.
What impresses me most is that ten years in, Meta's growth is accelerating, not fading. Revenue rose 22% in 2025 to $201.0 billion, and the growth rate stepped up through the year, from 24% year over year in the fourth quarter to 33% in the first quarter of 2026, when revenue hit $56.3 billion. The formula hasn't changed, either. The company sells more ads, at higher prices, across Facebook, Instagram, WhatsApp, and Messenger. Ad impressions rose 19% year over year in the first quarter, the average price per ad rose 12%, and an average of 3.56 billion people used at least one of Meta's apps each day in March.
All that advertising produces enormous profits. Meta's first-quarter operating income rose 30% year over year to $22.9 billion. And shareholders are seeing plenty of the cash. The company spent over $26 billion on share repurchases in 2025, paid another approximately $5 billion in dividends and dividend equivalents, and still ended the year with more than $81 billion in cash and marketable securities.
And the company is spending like it believes the next decade holds more. Meta recently raised its 2026 guidance for capital expenditures to a range of $125 billion to $145 billion, much of it aimed at AI infrastructure. Its second-quarter outlook, meanwhile, calls for revenue of $58 billion to $61 billion.
"We had a milestone quarter with strong momentum across our apps and the release of our first model from Meta Superintelligence Labs," said Zuckerberg in the company's first-quarter earnings release.
That spending is also the market's biggest worry about the stock. If the AI investments don't pay off in continued growth, today's expense ramp could weigh on profits for years to come. This past week, at least, investors treated the spending as a positive.
Today's Change
(
6.16
%) $
38.92
Current Price
$
670.40
Should investors expect a repeat? Sure, the backtest is fun. But nobody should buy Meta stock expecting another 19% a year for a decade. The company is vastly larger today than it was in 2016, and growth can get harder with size. Additionally, competition for attention and ad dollars isn't easing, and regulators around the world continue to scrutinize the company.
But the stock's price doesn't demand a repeat, either. Shares trade at about 19 times forward earnings -- a reasonable multiple for a company that just grew revenue 33% year over year -- even accounting for the risks of a $125 billion-plus spending plan. That valuation multiple, of course, could come down if growth slows, but this multiple also hardly assumes another decade of dominance.
After all, the lesson of the decade-long backtest isn't that Meta was a once-in-a-generation bargain in 2016. It's that an enormously profitable business kept compounding while plenty of investors found reasons to sell along the way.
For long-term investors, I think Meta remains a solid holding today. I just wouldn't let a $58,000 backtest set my expectations for the next ten years.
Trh se stablecoiny od květnového maxima ztratil asi 10 miliard USD; v červnu klesl o 7,7 miliardy USD na zhruba 312,23 miliardy USD, nejvíc od kolapsu TerraUSD.
The stablecoin market has lost about $10 billion since reaching a record high in May 2026. Total supply fell by $7.7 billion during June to about $312 billion, marking the largest monthly decline in dollar terms since the TerraUSD collapse in May 2022. The decrease equaled roughly 2.4% for June and about 3% from the May peak.
Summary
Stablecoin supply lost $10 billion since May as USDT and USDC redemptions reduced crypto liquidity. June recorded the largest monthly dollar decline since Terra, but the market contracted only 3%. Transaction volumes remained strong while tokenized assets expanded, showing blockchain finance activity continued despite redemptions. Current DefiLlama data places the market near $312.23 billion. The dashboard shows Tether’s USDT at about $184.15 billion and Circle’s USDC at roughly $73.41 billion. USDT still controls close to 59% of the market, leaving the sector heavily dependent on its two largest dollar-backed tokens.
USDT and USDC lead the supply reduction USDT fell from about $190 billion in May, cutting roughly $6 billion from its circulating value. USDC declined from a March peak near $80 billion, losing almost $7 billion over four months. Together, those changes account for most of the retreat, although smaller regulated issuers continued expanding during the same period.
Paul Howard, senior director at trading firm Wincent, described the decline as “a relatively small pullback in what we believe is a long-term growth market.” The current drawdown remains far below the 26% stablecoin contraction recorded across the 2022 bear market. That earlier decline followed the Terra failure, lender collapses, and the failure of FTX.
Stablecoin Market Loses $10B Since May in Biggest Retreat Since the Terra Crash
According to CoinDesk, stablecoin market capitalization has fallen by roughly $10 billion from its May peak, including a $7.7 billion drop in June—the largest monthly decline in dollar terms since… pic.twitter.com/RafAPoaerJ
— Wu Blockchain (@WuBlockchain) July 12, 2026 Lower supply points to thinner crypto liquidity Traders use stablecoins as settlement assets and quote currencies across exchanges and decentralized markets. A falling supply can show that users redeemed tokens for bank dollars or moved capital outside crypto. It can also reduce the amount of dollar-linked buying power available for Bitcoin, Ether, and other digital assets.
The reduction arrived during a weak month for crypto investment products.Crypto.news reported that U.S. spot Bitcoin exchange-traded funds lost more than $4 billion in June, their worst monthly outflow since launch. The parallel declines show that institutional fund demand and on-chain dollar liquidity both weakened as digital asset prices remained under pressure.
Activity did not fall at the same pace as supply. The adjusted stablecoin transaction volume reached a record $1.78 trillion in June. USDC processed about $1.21 trillion, while USDT handled $573 billion. USDT still recorded more individual transfers, showing that fewer tokens can continue supporting heavy payment and trading activity.
Tokenized assets grow while stablecoins retreat Tokenized real-world assets moved in the opposite direction. However, their on-chain value crossed $30 billion during 2026, led by tokenized Treasury products, funds, and private credit. CoinDesk Research also recorded a 145% rise in tokenized equity volume during June to a record $3.86 billion.
Regulation and new issuers continue reshaping the stablecoin market. The U.S. GENIUS Act created a federal framework for payment stablecoins, while regulators are drafting customer identification, sanctions, and reserve rules. Crypto.news has also tracked new reserve products from Fidelity and State Street designed for regulated issuers.
The latest supply figures point to a pause in market expansion rather than a Terra-style collapse. USDT and USDC remain near their dollar pegs, transaction activity remains high, and the total market retains most of its recent growth. Further monthly contractions would provide clearer evidence that crypto liquidity is leaving the system rather than moving between issuers or on-chain products.
Investors will now watch July issuance, redemption data, exchange volumes, and ETF flows for signs that demand is returning or weakening further.
BlackRockův BUIDL na Avalanche překročil 900 milionů USD v AUM, zhruba dvojnásobek oproti 464 milionům před týdnem. Jde o největší tokenizovaný treasury produkt on-chain na Avalanche.
BlackRock’s BUIDL, a tokenized U.S. Treasury money market fund on the Avalanche blockchain, has reached over $900 million in assets under management (AUM). This notable increase, from approximately $464 million just a week ago, highlights a significant surge in institutional interest in tokenized assets on Avalanche. The BUIDL fund, maintaining a stable value of $1.00 per token with daily accrued dividends, has become the largest tokenized treasury product on-chain and the biggest real-world asset (RWA) on Avalanche. This development underscores Avalanche’s rising prominence as a key player in the institutional tokenization sector, second only to Ethereum in terms of BUIDL’s AUM.
Advertisement
Key Takeaways BlackRock’s BUIDL fund on Avalanche has seen its AUM increase from $464 million to over $900 million within a week. The rapid growth in BUIDL’s AUM suggests accelerating institutional adoption of Avalanche for tokenized assets. Avalanche is now the second-largest blockchain for BUIDL by AUM, reinforcing its role as a leading institutional tokenization venue. What to Watch The surge in BUIDL’s AUM could indicate broader institutional adoption of blockchain-based financial products, potentially influencing Ethereum price predictions. Market participants may monitor whether this trend continues and if other blockchains follow suit in attracting large institutional investments. Observers will also be keen to see if BlackRock’s growing involvement in tokenized assets impacts Ethereum-related markets and if similar trends develop within the Ethereum ecosystem.
Get live prediction-market analysis, powered by Vera. Sign up for Vera.
Term Structure
Contract Odds Δ since publish Volume 24h August 1 2026 59.5% — — View market → August 1 2026 3.2% — — View market → August 1 2026 30% — — View market → August 1 2026 6% — — View market → August 1 2026 2.2% — — View market → August 1 2026 0.1% — — View market → August 1 2026 14% — — View market → August 1 2026 13% — — View market → August 1 2026 1.6% — — View market → August 1 2026 2.8% — — View market → August 1 2026 4.2% — — View market → August 1 2026 6.6% — — View market → August 1 2026 0.3% — — View market → August 1 2026 0.2% — — View market → August 1 2026 0.4% — — View market → August 1 2026 0.9% — — View market → August 1 2026 59.5% — — View market →
Solstice Advanced Materials koupí Element Solutions v hotovostně-akciové transakci za zhruba 14,5 miliardy USD včetně dluhu. Spojená společnost se zaměří na elektroniku, datová centra a tepelné řízení.
Element Solutions Forming Flat Base After Q2 Earnings Solstice Advanced Materials said it has agreed to acquire Element Solutions NYSE: ESI in a cash-and-stock transaction valued at approximately $14.5 billion, including the assumption of net debt, as the companies outlined plans to create a larger advanced materials platform with a heavier focus on electronics, data centers and related thermal management applications.
Get Element Solutions alerts:
Under the agreement, Element Solutions shareholders will receive $10 in cash and 0.5 shares of Solstice common stock for each Element Solutions share. Solstice President and CEO David Sewell said the offer represented a 15% premium to Element Solutions’ closing share price on Friday. Upon closing, Element Solutions shareholders are expected to own approximately 44% of the combined company.
The transaction is expected to close in the first half of 2027, subject to approvals from both companies’ shareholders, regulatory approvals and customary closing conditions. The combined company will operate as Solstice, with Sewell serving as CEO. Element Solutions CEO Ben Gliklich is expected to join Solstice’s board, along with two other designees from Element Solutions’ board, subject to standard governance procedures.
Companies Emphasize Electronics and Data Center Growth Sewell said the deal accelerates Solstice’s strategy as an independent company and creates what he described as a global advanced materials leader with expected combined 2025 net sales of approximately $6.8 billion and adjusted EBITDA of $1.7 billion. He said the combined company would have leading positions across end markets and more than 8,300 patents and pending applications.
Solstice executives framed the acquisition around the growth of advanced computing, artificial intelligence and data centers, particularly the need for materials used in semiconductor fabrication, advanced packaging, assembly and thermal management.
“We believe this combination creates an unmatched electronic materials platform,” Sewell said, adding that the portfolios are “highly complementary” across semiconductor fabrication, packaging, assembly and thermal management.
Gliklich said Element Solutions has been positioning its businesses toward faster-growing, higher-value customers and markets. He noted that Element Solutions generates just over 70% of its revenue from electronics, with about 75% of electronics sales coming from business-to-business markets. He also said more than 20% of Element Solutions’ sales come from the data center market and that percentage is growing.
Gliklich said the deal combines Solstice’s expertise in synthesis and engineering with Element Solutions’ expertise in formulation, process chemistry and applications development. He said the combination should help accelerate innovation and time to market.
Synergies and Financial Targets Solstice said it has identified more than $180 million in expected annualized run-rate cost synergies on a net basis, which it expects to realize within three years of closing. Sewell broke down the expected savings as follows:
Approximately $100 million from operational initiatives and operating model integration, including efficiencies in G&A, sales and marketing, and R&D; About $25 million from supply chain improvements, including raw material and procurement scale and copper recovery from deposition processes; Around $20 million from footprint optimization; About $35 million from other initiatives. Solstice CFO Tina Pierce said the combined company, including run-rate synergies, is expected to have an adjusted EBITDA margin of approximately 26%. She said revenue is expected to grow at a mid- to high-single-digit rate over the medium term, with adjusted EBITDA growing faster than revenue as synergies phase in. Pierce also said the company expects cash conversion of approximately 75% and expects the transaction to be accretive to adjusted earnings per share in year one.
Solstice expects net leverage of approximately 3.5 times at closing and said it anticipates deleveraging to below 3 times within 18 months after the transaction closes. Pierce said the longer-term net leverage target is 2 times to 3 times, in line with the company’s current credit rating profile.
Portfolio Fit and Integration Plans Sewell said Solstice’s strengths are concentrated in front-end semiconductor fabrication, including chemistries used in deposition, patterning, etching and cleaning. Element Solutions, he said, largely complements those capabilities in advanced packaging, printed circuit board building and assembly. He highlighted copper interconnects and thermal management as areas where the companies believe they can offer more complete solutions together.
In response to analyst questions, Sewell said the timing of the deal reflected the importance of advanced electronics to Solstice’s long-term strategy and the increasing demands customers are placing on suppliers for solutions. He said the integration is expected to be manageable because of the complementary nature of the businesses, though he stopped short of calling it a simple “drop-in” acquisition.
Gliklich said Element Solutions was approached by Solstice and had not put itself up for sale. He described the offer as attractive for Element Solutions shareholders because it includes upfront cash, a premium and continued participation in the expected value creation through Solstice stock.
Executives also said they see potential revenue synergies, though Pierce said the company’s revenue growth target depends only on a relatively small amount of revenue synergy. Sewell said some opportunities could come from cross-selling into each company’s customer base, while longer-term opportunities may require qualification processes that could take about two years.
Asked about possible divestitures, Sewell said it was premature to provide details but said the transaction gives Solstice more flexibility to tailor its portfolio to its long-term vision. He said the combined company would not be a pure-play electronics company, emphasizing that refrigerants and nuclear services also fit into Solstice’s view of data center infrastructure, including cooling and power needs.
Solstice executives said planned investments, including Kuprion facilities at Element Solutions and Solstice’s nuclear expansion and sputtering targets expansion, are included in the company’s financial model. Sewell said those investments are not expected to prevent the company from meeting its deleveraging goals.
About Element Solutions NYSE: ESIElement Solutions Inc is a global specialty chemicals company that develops and supplies highly engineered chemistries to performance-driven end markets. The company's solutions serve customers across the electronics, energy, transportation, consumer and industrial sectors, with a particular emphasis on electronics chemicals, metal plating, and industrial coatings additives.
In the electronics market, Element Solutions provides a range of plating and surface-treatment chemistries used in the manufacture of printed circuit boards, semiconductor devices, and advanced display technologies.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Element Solutions Right Now?Before you consider Element Solutions, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Element Solutions wasn't on the list.
While Element Solutions currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Equifax podepsal definitivní dohodu o koupi Círculo de Crédito v Mexiku za podnikovou hodnotu 750 milionů USD. Transakce má být uzavřena ve 4. čtvrtletí.
FICO’s Big Dip Could Be the Best Buying Chance of the YearEquifax NYSE: EFX said it has signed a definitive agreement to acquire Círculo de Crédito, which Chief Executive Officer Mark Begor described as the fastest-growing credit bureau in Mexico, for an enterprise value of $750 million.
During an investor update call, Begor said the acquisition would expand Equifax into Mexico, “the second largest economy in Latin America,” and give Círculo de Crédito customers access to Equifax’s cloud-native technology, decisioning and analytics capabilities, EFX.AI technology, and identity protection and fraud prevention offerings.
Get Equifax alerts:
3 Stocks Just Announced Intentions to Buyback Near 10% of SharesThe transaction is expected to close in the fourth quarter, subject to customary closing conditions and regulatory approvals. Begor said Equifax has been focused on entering Mexico for years, including efforts during prior leadership, and that Círculo became the most attractive entry point after TransUnion acquired majority ownership in another Mexican bureau.
Financial Terms and Expected Impact Equifax said Círculo generated $134 million in revenue for the 12 months ended June 30, up 31%, with adjusted EBITDA margins of 46%. For full-year 2026, Círculo is expected to continue delivering high double-digit revenue growth with mid-40% adjusted EBITDA margins, according to Begor.
4 Undervalued Growth Stocks to Buy and Hold for the Long TermThe $750 million enterprise value represents an 11.7 times adjusted EBITDA multiple at closing based on Círculo’s expected 2026 adjusted EBITDA, Begor said. Including expected run-rate synergies, the multiple is expected to be about 9.4 times at closing.
Begor said the acquisition is expected to be accretive to Equifax adjusted earnings per share in the first full year of ownership and to deliver mid-double-digit returns, which he said would be “well above” Equifax’s cost of capital.
Equifax also said it expects to maintain balance sheet leverage below 3 times while completing the acquisition. Begor said the company expects free cash flow to exceed $1 billion in 2026 and has more than $1.5 billion in financial capacity. He said Equifax can complete the acquisition while continuing share repurchases, though at a slower pace than in the first half of 2026.
Mexico Market and Círculo’s Position Begor characterized Mexico as one of the fastest-growing credit markets globally, with consumer credit growth driven by expanded access to credit, financial inclusion and digitization. He said more than 25% of Mexico’s population lacks access to formal financial products and nearly 44% does not have a bank account.
Círculo is the only credit bureau in Mexico licensed to operate both consumer and commercial credit bureau services, according to Begor. He said the company has more than 1,700 customers across banks, retail, fintech, small business lending, microfinance and telecommunications, along with 2 billion trade lines covering 80 million validated identities.
Begor said Círculo’s growth has been supported by its position in alternative data, including gig economy transactions and utility payment history. He said more than 40% of Círculo’s 2025 revenue came from fintech customers, with that segment growing more than 50%.
Integration Plans and Synergies Equifax said it expects to generate synergies by deepening Círculo’s retail and fintech data position, expanding penetration with large financial institutions, and moving Círculo’s infrastructure onto Equifax’s cloud-native architecture.
Begor said Equifax plans to bring its global platforms and products into Mexico, including its Ignite analytics platform, InterConnect platform, scores, AI capabilities, fraud tools and identity products. He also said Equifax expects some Círculo products and fintech-related capabilities to be deployed in other markets.
The company pointed to its acquisition of Boa Vista in Brazil as a model for the Círculo integration. Begor said Boa Vista has outperformed Equifax’s expectations and gave the company confidence in its acquisition integration playbook.
Questions From Analysts In response to questions about Círculo’s recent growth, Begor said the company has benefited from the rapid expansion of fintechs, retailers and telecommunications providers in Mexico. He said many consumers without bank accounts may first build credit through retail financing, such as appliance or furniture purchases.
Asked about competition, Begor said TransUnion is currently in the Mexican market through its ownership of the previously bank-owned consumer credit bureau. He said Equifax believes Círculo is well positioned because of its data from retailers, fintechs and telecommunications providers.
Begor also addressed Mexico’s data-sharing structure. He said credit bureaus are required by law to share certain trade lines when a credit report is pulled, but positive data is unique to each bureau. He said Círculo’s positive data, more frequent reporting from some contributors and broad contributor base are important advantages.
On regulatory timing, Begor said Equifax believes its approval process could be faster than TransUnion’s recent acquisition process because Equifax has had an application with Mexican regulators for several years to form a credit bureau and has been engaged with them during that period.
Equifax said the Círculo transaction is part of its broader bolt-on acquisition strategy. Including Círculo, Begor said the company will have invested nearly $5 billion in 17 strategic bolt-on acquisitions since 2020, focused on differentiated data, workforce solutions, international markets, and identity and fraud capabilities.
About Equifax NYSE: EFXEquifax Inc NYSE: EFX is a global data, analytics and technology company that specializes in consumer and commercial credit reporting, decisioning tools and identity solutions. Headquartered in Atlanta, Georgia, Equifax is one of the three major consumer credit reporting agencies in the United States and provides credit information and related services to lenders, employers, governments and consumers worldwide.
The company's offerings include consumer credit reports and scores, credit monitoring and identity protection services, and a range of business-oriented products for risk management, fraud detection and compliance.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Equifax Right Now?Before you consider Equifax, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Equifax wasn't on the list.
While Equifax currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
SanDisk už spustil výrobu BiCS10 s o 59 % vyšší bitovou hustotou, což snižuje riziko před komercializací. Tržby datových center vzrostly mezikvartálně o více než 230 % díky AI inferenci, KV cache a poptávce po enterprise SSD.
SummarySanDisk's BiCS10 delivers 59% higher bit density while production has already begun, reducing execution risk well ahead of commercialization. Data center revenue surged more than 230% sequentially as AI inference, KV cache and enterprise SSD demand become the primary growth drivers. Five multi-year agreements secure approximately $42 billion of minimum revenue with over $11 billion of financial guarantees, fundamentally improving earnings visibility. Although SanDisk trades at roughly 29x forward earnings versus Micron's 13x, the premium reflects expectations of a structurally less cyclical business model. denisik11/iStock via Getty Images
The recent sharp fall in SanDisk (SNDK) over the last two weeks was seen as proof that the rally was just getting ahead of itself. I believe this overlooks the fundamental changes occurring inside the
8.25K Followers
Analyst’s Disclosure: I/we have a beneficial long position in the shares of SNDK, MU either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Microsoft začal u některých promptů v Excelu a Outlooku používat vlastní modely MAI místo OpenAI a Anthropic, aby snížil náklady. Podle Bloombergu už na nich běží desítky tisíc promptů týdně.
Microsoft Corp. NASDAQ: MSFT has taken steps to lessen its reliance on frontier AI models, though it's not an outright declaration of protest. In June, the tech giant launched its own proprietary AI models (Microsoft AI or MAI) across select applications in its Office suite.
What this means for the user experience is an open question, but this is a clear margin play for Microsoft. The company competes in multiple areas of the AI infrastructure buildout. In a way that makes this move about controlling the controllables.
Get Microsoft alerts:
Instead of experiencing death by a thousand cuts from OpenAI and Anthropic (i.e., the frontier models), Microsoft is trying to widen its existing moat and deliver strong returns on investment (ROI) from its AI spend. But will this be sufficient to alter the sentiment towards MSFT, which has declined approximately 20% year-to-date?
Microsoft Expands MAI to Reduce Reliance on OpenAIHere's the news behind the news. Bloomberg reported that Microsoft is quietly routing some Excel and Outlook prompts to MAI, its in-house model family, rather than to OpenAI or Anthropic. Tens of thousands of prompts a week are already running on Microsoft's own tech.
That's still a small slice of total Copilot traffic. OpenAI and Anthropic handle most of it today. But the direction of that travel matters more than the current split, and Microsoft has made its intentions clear.
At Build 2026 in June, Microsoft unveiled seven MAI models, including its first reasoning model, MAI-Thinking-1. The company says it matches Anthropic's Claude Opus 4.6 on coding tasks. AI chief Mustafa Suleyman put it bluntly: "We pay a lot of money to Anthropic, so our goal is to reduce and ultimately eliminate that cost."
How Microsoft's In-House AI Could Boost Profit MarginsFor investors, an easy way to think about this is as follows. Copilot is a $30-per-seat subscription that, prior to the MAI launch, was running on top of someone else's expensive AI model by default. Every prompt costs Microsoft money to process, and multiplied across hundreds of millions of Office users, that bill adds up fast.
Owning the model instead of renting it changes the equation entirely. Microsoft doesn't need MAI to win over every customer. It just needs MAI to be good enough for everyday spreadsheet formulas and email drafts, at a fraction of the cost.
That's the ROI story. Microsoft won’t win an AI arms race on raw intelligence. But it can compete more efficiently by converting a rented cost center into owned infrastructure.
Microsoft Uses MAI to Strengthen Its AI Competitive MoatMicrosoft chief executive officer (CEO) Satya Nadella has reportedly said he feared Microsoft becoming "the next IBM.” By that, he meant a company that let someone else own the most important layer of technology. MAI is Microsoft's answer to that fear.
Instead of a single point of AI dependency, Microsoft now runs a three-way hedge. It holds a stake in OpenAI, embeds Anthropic's Claude in Copilot, and increasingly leans on its own models where the economics make sense. That flexibility is arguably a bigger moat than any one model's benchmark score.
It also insulates Microsoft from a ticking clock. Microsoft's current discounted OpenAI pricing won't last forever, and that deal isn't set to expire until 2032. Building a credible in-house alternative now gives Microsoft leverage in any future renegotiation, rather than leaving it stuck paying whatever OpenAI or Anthropic decides to charge.
The Bear Case: Risks to Microsoft's AI StrategyBefore getting too bullish, a few caveats are worth weighing. This shift is still incremental, and Microsoft hasn't published any timeline for expanding it further. Most Copilot workloads still run on outside models today.
There's also a quality question. Microsoft's own materials frame MAI as matching prior-generation Anthropic models, not necessarily the current large language models (LLMs). If MAI-powered features feel noticeably worse, customer goodwill could take a hit that outweighs the cost savings.
What It Means for OpenAI and AnthropicThis is a warning shot worth watching. Anthropic filed confidentially for an IPO in June, and OpenAI is reportedly preparing a similar filing. Their biggest enterprise distribution partner is now also a competitor, building cheaper in-house alternatives.
That doesn't mean OpenAI or Anthropic are in immediate trouble. Both still handle the bulk of Copilot's AI traffic, and Microsoft has made it clear that it isn't ending either partnership. But the "picks and shovels" trade just got a little more complicated for anyone betting purely on third-party AI labs staying indispensable.
Microsoft Stock Rebounds After Hitting a 52-Week LowMicrosoft hit a 52-week low in late June. The 10% bounce off that level isn’t a sign that everything is perfect, but it does suggest that investors are leaning into the stock’s value proposition.
At around 22x forward earnings, Microsoft is trading at a discount to the S&P 500 and to its own history. An argument could be made that MSFT wasn’t overvalued when the sell-off began in November, and there’s ample reason to believe it’s undervalued now. The relative strength indicator reached oversold territory when MSFT bottomed in June.
But a larger story comes from analysts and institutions. The MSFT consensus price target of $559.84 is approximately 45% below its recent trading range. Plus, out of 48 analysts tracked by MarketBeat, 41 give MSFT a Buy rating, and seven rate it as a Hold. Analysts notoriously don’t like to be wrong, which may explain why some analysts have trimmed their price targets, but the overall sentiment remains bullish.
The same cautious optimism can be found in its institutional ownership. There's no question that buying has slowed in the first two quarters of the year. But buying still outpaces selling, and with MSFT at 22x earnings, this could be an attractive target for money that hasn’t left the market and is looking for growth in the second half.
Should You Invest $1,000 in Microsoft Right Now?Before you consider Microsoft, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Microsoft wasn't on the list.
While Microsoft currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.
"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Delta Air Lines ve 2. čtvrtletí 2026 zvýšila výhled na celý rok a tržby meziročně vzrostly o 18,7 %. Upravený zisk na akcii (EPS) byl 1,56 USD, nad odhady.
Delta Air Lines NYSE: DAL lived up to its motto, with the Q2 2026 earnings results showing strength, suggesting its shares can Keep Climbing. Drivers include outperformance driven by international demand, overall demand, premiumization, and structural cost advantages, which together provide ample cash flow.
Delta Air Lines Today
DAL
Delta Air Lines
$87.48 -1.52 (-1.70%)
As of 07/10/2026 03:59 PM Eastern
This is a fair market value price provided by Massive. Learn more.
52-Week Range$50.44▼
$95.68Dividend Yield0.98%
P/E Ratio14.51
Price Target$97.06
The critical detail in the release was the guidance, which forecasts that these trends will continue. More importantly, guidance was raised, prompting a robust response from analysts.
Get Delta Air Lines alerts:
While no upgrades or price target revisions were tracked within the first hours of the release, several commentaries hit the wires. Analyst commentary reaffirms the robust trends, including numerous initiations, upgrades, and price target increases ahead of the earnings release on July 10.
As it stands, MarketBeat tracks 27 analysts rating DAL as a consensus Moderate Buy; coverage is up versus the prior month, quarter, and year, with sentiment firming and an 89% Buy-side bias in the data. The consensus price target assumes fair value near the early-July highs, but the trend matters. Recent revisions place this market in the high-end range, between $100 and $116, which would be a fresh all-time high when reached.
Delta’s July Pullback: A Touch-and-Go Event, Buy the DipDelta’s price pullback reflects a market expecting strength, as the Q2 results and guidance revealed nothing but that. Revenue growth accelerated sequentially and year over year with a robust 18.7% advance, ahead of expectations.
Delta’s strength was seen across metrics, underpinned by a mere 1% increase in capacity. Total revenue per average seat mile (TRASM) grew by 12.4%, with strength in the main cabin and premium, which grew by 17%. Domestic revenue grew by 12% and international revenue by 8%, with cargo up by 39% and maintenance services by 32%. Loyalty, a forward-looking indicator, grew by 19%, and corporate traffic grew by double digits.
While margin contracted in the quarter, and slightly more than expected, the contraction was minimal. More importantly, top-line strength carried through to the bottom line, leaving the adjusted earnings per share of $1.56 above forecasts by 400 bps. Looking ahead, the company expects strength to continue and reaffirmed its guidance. The critical details are that free cash flow and capital returns will continue, and that the guidance may be cautious. Travel trends remain robust across leisure and business segments, potentially accelerated by falling energy prices.
Delta’s Cash Flow Recovery Story Takes FlightDelta’s stock price recovery is underpinned by growth but, more importantly, the cash flow it produces. Drivers of the share price include persistent debt reduction, improving investment-grade balance-sheet quality, and the return of capital to shareholders.
Q3 capital returns included dividends but no share buybacks, with the dividend annualizing to about 1%. The payout ratios reveal no red flags for investors, as the company is in a position to continue executing its strategy while increasing its dividend annually. Balance sheet highlights include increased cash, reduced debt, and improving equity, with equity up 4.6% year to date.
Institutional activity reflects the potential in a DAL investment. The group owns a substantial 70% of the stock and has been accumulating at a nearly $2-to-$1 pace over the trailing 12 months. They provide a solid support base and market tailwind that will likely remain in place, given the guidance. In this scenario, DAL’s share price might continue pulling back in Q3, but the downside is limited, and higher share prices are likely by year’s end. Critical support targets are near $85 and $80; lower lows are unexpected.
Delta’s risks center on cost controls and execution. Costs, including labor, continue to rise while a major C-suite transition is underway. Two retirements and one exec’s departure for new opportunities resulted in several promotions and consolidated roles. The risk lies in disruptive hiccups tied to the role changes, specifically during the upcoming seasonal shift. If Delta fails to match capacity to demand, it risks losing pricing power, which would be detrimental to both top- and bottom-line results. In the longer term, Delta is expected to sustain modest growth over the next five years.
The stock price action is favorable, despite the early Q3 price pullback. Delta is rising on a wave of strength, cash flow, and dividends that has yet to play out, leaving the underlying uptrend intact. The likely outcome is that support kicks in at or near the early July lows, leading to a trend-following signal and price rebound later this year. Signals of strength include MACD convergence on the weekly chart, suggesting the latest highs will at least be retested, and support at the 30-day exponential moving average.
Should You Invest $1,000 in Delta Air Lines Right Now?Before you consider Delta Air Lines, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Delta Air Lines wasn't on the list.
While Delta Air Lines currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.
